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The study of tumor development, tumorigenesis, offers to elucidate the basic 
biologic mechanisms controlling the clinical characteristics of neoplasms and their 
precursors. The importance of this work becomes clear when considering the prognostic 
tools and therapeutic advances made possible by knowledge of the development of 
invasive disease: Histopathologic classification of tumor grades informs staging and 
underwrites prognosis and treatment discussions. Efforts to define imaging characteristics 
of developing lesions allow detection of neoplastic processes when they are often more 
effectively managed. A new generation of biologic and immunologic agents promises a 
future of personalized treatments largely based on better understanding of the expansion 
of tumor lineages and the epigenetic changes that drive them.  
Many of these insights draw from efforts at modeling the order and behavior of a 
spectrum of lesions that populate a particular oncologic process. A prominent example is 
adenocarcinoma of the colon wherein a series of precursor lesions have been paired with 
characteristic molecular and clinical changes. This model and its understanding that 
select pathways of tumorigenesis showed reliance on vascular endothelial growth factor 
(VEGF) receptor signaling led to targeted treatment selection with anti-VEGF antibodies 
such as bevacizumab. 
Similar modeling has proven particularly useful in the study of breast cancer, a 
heterogeneous group of diseases with multiple lineages and a large spectrum of pre-
invasive lesions. Histopathologic characterization and empirical clinical investigation 
have been supplemented by molecular approaches in efforts to appropriately tailor studies 
! A!
and treatments to each subtype. The earliest ‘targeted’ therapies in oncology capitalized 
on these efforts, including the selection of estrogen receptor (ER) positive patients for the 
adjuvant antagonistic hormonal therapy tamoxifen and trastuzumab usage in HER2/neu-
overexpressing tumors.1 Continuing efforts to extend this strategy focus on genetic 
alterations in key genes, global expression profile patterns, and gene copy number.2 
Despite the increased incidence of overall disease, a combination of screening 
mammography and treatment advances has contributed to a decline in mortality in the 
Western World.3 
At the same time, the very success of screening has introduced uncertainty 
regarding treatment selection for patients who increasingly present with pre-invasive 
disease. As attention has turned to these lesions, there has been renewed focus on the 
crucial stages of tumorigenesis that dictate whether a lesion will become invasive and 
require treatment or not. In this context, Ductal Carcinoma In Situ (DCIS), a pre-invasive 
breast lesion, has figured prominently. The importance of DCIS, its role in breast 
tumorigenesis, and the gaps in knowledge surrounding its management will be reviewed 
here as a rationale for the study conducted. Furthermore, the technical advances that 
allow such investigation will also be described. 
Biology of Ductal Carcinoma In Situ 
DCIS is defined as a clonal proliferation of malignant appearing cells confined to 
the lumen of a mammary duct without evidence of penetration through the epithelial 
basement membrane.4,5 DCIS is considered an immediate precursor lesion to invasive 
breast cancer (IBC)6 with some suggesting it specifically gives rise to Invasive Ductal 
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United States.7 Traditional models of tumorigenesis in ductal breast tumors have 
described a linear progression of lesions beginning with benign proliferative changes and 
culminating in DCIS that corresponds to an accumulation of genetic alterations (Figure 
1).8 Despite a large body of work on invasive breast disease, the initiation and 
culmination of the tumorigenesis process remains poorly defined. Nonetheless, multiple 
lines of investigation strongly support DCIS as a fundamental evolution of tumor biology 
in this progression due to a) its similarity to invasive disease and b) its distinction from 
less advanced precursor lesions. 
    
DCIS Closely Resembles Invasive Disease on a Molecular Level 
Most invasive ductal breast disease is thought to arise from DCIS in a clonal, 
evolutionary manner. Evidence for this relationship has been drawn from the 
conservation of mutations and chromosomal changes in this progression. Loss of 
heterozygosity (LOH) analysis first established this comparison on the basis of shared 
allelic imbalances between DCIS and synchronous, adjacent invasive disease. 9,10 The 
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development of comparative genomic hybridization (CGH) allowed investigators 
subsequently to deepen this evidence with whole genome DNA copy number data.11-13 
The high incidence of mutations such as in p53,14 over-expression of the proto-oncogene 
HER2/neu,15 and loss of estrogen receptor (ER) expression4 in DCIS similarly mirrored 
the findings in associated invasive disease. Indeed, no mutations unique to invasive 
disease have been identified yet on comparison to DCIS. Gene expression profiling 
likewise has demonstrated highly similar patterns in coincident invasive disease and 
DCIS.16-20  
The heterogeneity of DCIS also parallels invasive disease. Histological study has 
differentiated DCIS into subtypes seen in invasive disease based on similar markers, such 
as hormone receptors and cytoskeletal proteins.21 On a molecular level, low- and high-
grade DCIS lesions have been correlated with distinguishing genetic alterations much 
akin to low- and high-grade invasive disease. While 75% of high grade lesions lose ER 
expression and two-thirds harbor p53 mutations or HER2/neu over-expression, 90% of 
low-grade lesions preserve ER expression while less than 20% over-express HER2/neu or 
contain p53 mutations.22 Low-grade lesions further are characterized frequently by 
chromosomal loss at 16q and gain at 1q in contrast with local amplifications in high-
grade lesions at 11q13 (CCND1) and 17q12 (ERBB2).12,23 Moreover, it seems these 
different populations of DCIS represent independent pathways of genetic evolution to 
IDC. Specifically, low-grade lesions are apparent direct precursors to IDC without 
requirement for evolution to high-grade DCIS first. Preservation of genetic changes and 
histological observation of synchronous, adjacent lesions argue that low-grade DCIS give 
rise to more differentiated IDC, whereas high-grade DCIS often gives rise to grade III 
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IDC.23-25 The heterogeneity of DCIS thus suggests it should be analyzed and managed 
clinically with greater resolution than currently is done. Nonetheless, all of these DCIS 
lesions seem to represent a stage of tumorigenesis at which most of the molecular 
changes that define invasive disease are already present.4  
DCIS is Molecularly Distinct from Less Advanced Precursors 
In contrast, the development of DCIS seems to be marked by distinctive clinical, 
histopathologic, and biologic features when compared with other presumptive precursor 
lesions such as Atypical Ductal Hyperplasia (ADH). CGH analyses of such lesions, 
including ADH,26-29 demonstrated that the copy number imbalance profiles of these 
lesions differ from invasive disease or DCIS. DCIS seemed to harbor more widespread 
changes.11,12 Further, work showing a stepwise accumulation of global LOH from 0% in 
normal breast tissue to 35-40% in ADH to >70% in DCIS suggested a linear order to 
these lesions culminating in DCIS.13,30-32 Key gene alterations common to invasive disease 
and DCIS, such as in p53 tumor suppressor mutation or HER2/neu proto-oncogene over-
expression, are rarely observed in ADH or other early proliferative lesions.14,15 Finally, 
the most dramatic gene expression pattern changes of tumorigenesis seemed to occur 
during the transition from normal tissue to DCIS.16-18   
Thus, most evidence suggests that DCIS evolves from other precursor lesions, 
namely ADH, and has accumulated most of the molecular changes of invasive disease to 
which it gives rise. In this sense, DCIS has been studied thoroughly for its significance in 
breast cancer tumorigenesis. At the same time, DCIS is a heterogeneous disease with 
distinct populations likely undergoing transitions to invasive disease with differing 
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latency and frequency. The factors affecting this latter transition remain poorly defined 
and constitute the most important information about its clinical management. 
Models of Progression of DCIS to Invasive Disease 
 While past work on DCIS has been unable to consistently differentiate DCIS from 
paired IBC, it is strongly suspected that a final series of events in the lesion drives the 
transition to invasiveness. The traditional progression hypothesis holds that the epithelial 
cells making up the lesion evolve based on such events, which are subtle and/or difficult 
to detect by previous study designs. However, notable inconsistencies in this ‘linear’ 
model have led to alternative theories that will be mentioned briefly here. These focus on 
a) the tumor microenvironment and b) stem cell populations.  
Microenvironment Theory 
The most obvious challenge to the traditional, ‘linear’ model of DCIS evolution is 
the lack of evidence thus far for genetic change in the epithelial cells of the lesion during 
progression. This problem is often attributed to the sub-optimal study design in the past 
caused by limitations on technical ability and access to ‘pure’ DCIS tissue. As an 
alternative, interesting new evidence suggests a role of tumor microenvironment in DCIS 
transition to IBC. Changes in DCIS are specifically documented in myoepithelial cells 
(MECs) and stromal cells, including fibroblasts and myofibroblasts. MECs are important 
in normal breast duct development and physiology, providing natural tumor suppressor 
functions.33,34 In contrast to ‘normal’ MECs, DCIS-associated MECs show down-
regulation of genes involved in normal duct function, while showing up-regulation of 
transcripts that support epithelial cell proliferation, migration, invasion, and stromal 
angiogenesis.35-37 Further, DCIS-associated MECs show distinct epigenetic38 and 
! ""!
Fig 2. The Sontag-Axelrod ‘parallel’ 
model of progression of ductal 
carcinoma in situ (DCIS) and 
invasive ductal carcinoma (IDC). 
This model holds that the two diseases 
diverge from a common progenitor cell 
and progress through different grades in 
parallel. The figure shows pairs of 
lineages of progression for DCIS and 
IDC through their respective histologic 
grades. The order in which DCIS and 
IDC begin their progression varies among 
the 5 listed sub-groups with their 
calculated percentages noted. The basis 
of this model overall lies in matching of 
mathematic modeling to clinically 
observed frequencies of grades of DCIS 
and IDC in co-existing disease. The 
projections of the parallel model outlined 
here matched most strongly with the data 
according to the authors. Figure adapted 
from Kuerer et al.. 
immunophenotypic changes.39 Similarly, stroma associated with DCIS has been 
associated with changes seen in invasive disease.40-42 However, little work has been done 
on following the microenvironment of DCIS as progression occurs, limiting 
interpretation to correlation rather than causation.  
A Common Stem Cell Progenitor for DCIS and IBC? 
Another alternative hypothesis for explaining DCIS to IBC transition is borne out 
of the contradiction between the predictions of the ‘linear’ model and the results of 
mathematical modeling. One notable study assessed four different models of progression 
for fit of clinical observations to expected frequencies of co-occurrence of DCIS and IDC 
of different grades.43 The ‘linear’ model, as well as the offshoot ‘branched’ and ‘non-
linear’ models, all assumed IBC arose from DCIS as traditionally thought. In contrast, a 
fourth ‘parallel’ model described DCIS and IDC diverging from a common progenitor 
cell and developing through different grades together (Figure 2). The authors found most 
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robust performance in the ‘parallel’ model. The results suggest the possibility that DCIS 
and IDC sprout from a common progenitor and that the critical molecular events driving 
clinical behavior of disease take place before DCIS morphology is manifest.6 Moreover, 
this theory would provocatively imply low utility for the standard of care treatment of 
DCIS to prevent IDC. 6  
However, like the traditional linear model and microenvironment theory, the 
‘parallel’ model relies on key missing data. In the linear model, this would be some 
genetic alteration associated with DCIS progression to IBC. For the microenvironment 
theory, a similar need for distinguishing factors in the microenvironment of DCIS that 
progresses to IBC has yet to be established. In the ‘parallel’ progression model, 
progenitor stem-like cells have been tentatively explored but none have been consistently 
validated. Thus, no biologic model yet exists to illuminate the mechanisms of progression 
in DCIS. 
Clinical Features and Treatment Issues 
The lack of biologic characterization of the ductal carcinoma in situ (DCIS) to 
invasive ductal carcinoma (IDC) transition underlies a lack of a precise clinical 
characterization. This gap in knowledge has inhibited refinement of disease management 
in a heterogeneous disease that continues to be treated with relatively homogenous 
measures. Nonetheless, in response to the large epidemiologic impact of the disease 
today, robust empirical clinical investigation has produced diagnostic and management 
guidelines with positive effect on mortality and morbidity. Current clinical management 
and the key prognostic dilemma of DCIS to IBC prediction will be reviewed here as 
background for the clinical significance of this study. 
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Diagnosis 
Diagnosis of DCIS historically relied on gross palpation of a mass or note of 
secondary effects such as nipple discharge or Paget’s disease of the nipple.4 Several 
advances in diagnosis in imaging, biopsy technique, and histologic assessment have 
enhanced sensitivity for early detection, though not without their own limitations.  
Most notably, the introduction of widespread mammography in the 1980’s has 
resulted in a >10x increase in the diagnosis of the disease in the U.S..44 Whereas only 
4800 cases were diagnosed in 1983, roughly 64,000 cases are diagnosed annually today.45 
DCIS now represents 15-25% of newly diagnosed breast carcinomas,44,45 increased from 
1-2% pre-mammography.46 In terms of sensitivity, 90% of DCIS cases diagnosed as 
suspicious calcifications on mammography.47 The specificity of this test is limited 
regarding the extent of involvement in multifocal disease48 and in those lesions without 
significant necrosis or calcifications.  
Stereotactic core needle biopsy is the tissue sampling modality of choice for 
suspicious lesions. Direct biopsy has drawbacks, which are compensated for in 
management guidelines. Namely, core needle diagnosis of atypical ductal hyperplasia 
often prompts wider, surgical excision for more extensive pathological assessment due to 
a 10-50% risk of concurrent invasive or in situ disease.49,50 Biopsy diagnosis of DCIS 
likewise shows a 10-15% incidence of concurrent invasive disease50,51 that increases with 
histologic grade. This further is one of the justifications for full resection. 
Following biopsy, histologic analysis primarily assesses for any invasive disease 
and aids in specification of the few characteristics that are known to affect DCIS 
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behavior. Close or involved margin status, presence of comedonecrosis, and high-grade 
are most consistently linked with increased risk of recurrence after resection.4,6  
Treatment 
Once the diagnosis of pure DCIS is made, the goal of treatment is to remove the 
neoplastic tissue and prevent recurrence. A series of large studies has produced robust 
data on the dominant treatment strategies that include excision +/- radiation.6,52 Currently, 
the standard of therapy is breast conserving surgery (BCS) followed by irradiation. 
However, significant variation in treatment still exists with a mix of therapies used 
including mastectomy with or without reconstruction, breast conserving surgery (BCS), 
and BCS with adjuvant radiotherapy53 with 10-year local recurrence rates of 1%, 30%, 
and 10%, respectively.52  
Historically, mastectomy was first employed with near complete cure rates. The 
finding that BCS offered identical survival to modified radical mastectomy in invasive 
breast cancer54 prompted concern that mastectomy may be overtreatment for some DCIS 
patients, particularly in that increasing cohort of cases with small lesions detected by 
mammography. While no direct randomized controlled comparison of mastectomy and 
BCS for DCIS exists, indirect, retrospective data from surgical trials55 and treatment 
registries56-58 indicate that mastectomy provides a locoregional recurrence benefit but no 
improved overall survival or rare disease-specific mortality,56,59 BCS is the most common 
surgical component of therapy today. 
Adjuvant whole-breast radiotherapy is often added to address the increased 
locoregional recurrence risk in BCS. This combination therapy has been evaluated in 3 
large randomized controlled trials in both the U.S. through the National Surgical 
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Adjuvant Breast and Bowel Project (NSABP) and Europe through the European 
Organization for Research and Treatment of Cancer (EORTC) and U.K. Coordinating 
Committee on Cancer Research (UKCC). NSABP B-17 showed a 58% reduction of 
locoregional recurrence at 12 years in the adjuvant radiotherapy group vs. BCS alone.60 
However, overall survival was not significantly affected. The EORTC and UKCC trials 
showed an identical pattern of benefit.61,62  
Irradiation comes with its own morbidity as well as time commitment. Moreover, 
in some subgroups of patients with DCIS, such as those with no histological high-risk 
factors for recurrence or of very old age, the absolute locoregional recurrence risk 
reduction seen in the adjuvant radiation trials was small.63 In response, some investigators 
have attempted predict which groups of patients may omit radiation. Notably, the Van 
Nuys Prognostic Index (VNPI) used a system of risk classification based on grade, width 
of margin, and size of lesion in which the lowest risk category would receive excision 
alone.64 However, neither this index nor any other predictive scoring system based on 
histology has successfully validated on prospective study.65-68 The reasons for this failure 
include the initial ‘validation’ of the index on retrospective sets, the use of samples across 
a long period of time that saw an evolution in treatment and diagnostic modalities, and 
poorly reproducible classification methodology.69 More fundamentally, the predictive 
index was unable to address the lack of understanding about the biology of the transition 
to invasiveness that would allow a more rigorous method for classifying heterogeneous 
DCIS. Thus, adjuvant radiation remains standard of care following BCS. 
Hormonal therapy has also been evaluated following successes in the treatment of 
invasive disease. 5-year adjuvant tamoxifen in patients treated with BCS and irradiation 
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was studied in NSABP B-2460,70 and the UKCC trial61 with conflicting results. While 
initial analyses on this discrepancy suggested benefit was isolated to ER+ groups,71,72 
others focused on younger patients (<50 years old).6 In either case, absolute risk 
reduction is considered marginal, and the side effects of increased thromboembolic 
events, endometrial cancer risk, and menopausal symptoms are particularly undesirable in 
the target group of young women.73 Like with adjuvant irradiation, development of more 
specific treatment stratification strategies for hormonal therapy is limited by a lack of 
biological discrimination of DCIS.  
Recurrence 
 Locoregional recurrence refers to ipsilateral breast lesions found subsequent to 
treatment of an initial malignant breast lesion. Half manifest as invasive disease in 
DCIS.74 The similarity of pathologic75 and genetic features76,77 to the index lesion suggest 
that recurrences most often arise from residual microscopic disease. Clearly, even with 
various treatment options available, some patients with biologically more aggressive 
lesions are being under-treated. The result is that these patients often must undergo 
salvage mastectomy with sentinel lymph node biopsy.78  
Prognostic Challenges 
 Thus, despite improved outcomes and reduced morbidity from empirical clinical 
investigation, it is clear that the treatment decision process at initial diagnosis of DCIS 
remains muddled by a lack of prognostic ability. Multiple histologic and demographic 
risk factors for recurrence have been described. Yet, the most publicized approach to 
tailoring treatment to a predictive index based on such risk factors, the VNPI, has failed 
repeatedly as described. No criteria exist to answer the fundamental question facing 
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DCIS management: which of these cases would progress to invasive disease without 
treatment and thus truly require treatment?  
 Study of the natural history of DCIS in an attempt to answer these questions is 
difficult. Standard management calls for full excision of the lesion. Even in those patients 
opting to defer care, the biopsy diagnosing the lesion often also removes it. The most 
useful data on rates of progression come from lesions that were initially misdiagnosed as 
ADH. The most thorough review suggests that these lesions progress to IDC at a rate of 
10-53% over a period of 10 or more years.79 This is a wide estimate that is plagued by the 
skew towards low-grade lesions that are more often mistaken for ADH.  
 Without better characterization of sub-group specific prognosis within DCIS, a 
homogeneous treatment approach will remain. The lesions treated today are 
fundamentally different in size and possibly biology from those initially used pre-
mammography to justify treatment, On the other hand, even with standard of care, a 
small fraction of cases will recur systemically and cause death. Thus, some populations 
likely receive over-treatment and others under-treatment. 
Molecular Approaches to Prognostic Prediction 
With histologic and demographic risk factors failing to translate into clinical 
predictive ability, attention has returned towards developing a better biologic 
understanding of the transition to invasiveness in DCIS. Ideally, this would involve the 
study of DCIS lesions as they evolve with comparisons before and after the onset of 
invasiveness. The major molecular investigations in this area have been hampered by 
technical limitations of design with both retrospective and prospective studies. Recent 
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improvements in technology have introduced possible solutions for these issues and serve 
as the methodology background for the study. 
Past molecular work on DCIS evolution has often focused on snapshot 
comparisons of DCIS of various grades and associations. For instance, Adeyinka et al.19 
supplemented earlier CGH work by demonstrating different grades and morphologies of 
DCIS could be discerned by gene expression analysis. Scheutz et al.80 and Ma et al.18 
conducted patient matched comparisons of synchronous DCIS and IBC. These studies 
have advanced the use of limited RNA in microarrays and solidified laser microdissection 
(LCM) as a method of purifying neoplastic epithelial cells in DCIS from contaminating 
stroma. However, they analyze IBC associated DCIS which are not representative of the 
‘pure’ DCIS that is the focus of the prognostic dilemmas described. None of these studies 
have made the critical comparisons of a given DCIS specimen before and after 
invasiveness arises and to DCIS that did not give rise to invasive disease. This line of 
investigation alone can properly assess the factors determining why some lesions 
progress and others remain stable as in situ lesions for long periods of time. 
Prospective Methodology Limitations and Advances 
Prospective studies are the most obvious setting for such a design. However, it is 
difficult to access the necessary DCIS tissue at initial resection because standard of care 
requires the entire specimen to be examined for evidence of invasive disease and margin 
status, both of which are critical to treatment decisions. This inhibits the ability to make 
comparisons to subsequent recurrences. However, the increased sensitivity of molecular 
analyses, especially gene expression arrays, has offered the potential of banking mRNA 
or expression data from core biopsy samples. Indeed, this has been accomplished peri-
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operatively in invasive disease albeit on more voluminous samples than DCIS usually 
offers.81 Nonetheless, given the estimated median latency of DCIS to IDC progression 
near a decade in length, comparative investigations of patient-matched samples will 
require much time for completion. Thus, they are usually best used as validation sets for 
candidate markers developed from retrospective data, as suggested by the experience 
with the failed Van Nuys Prognostic Index, or as an adjunct to a retrospective study. 
Retrospective Methodology Limitations and Advances 
Retrospective work has the benefit of clinical follow up data on recurrence and 
outcome matched to the samples to be analyzed. Further, unlike prospective trials, they 
can be done relatively quickly if existing tissue and data banks are identified. Molecular 
analysis of these samples is challenging given the alterations to nucleic acids and proteins 
in the storage process, which usually produces with a formalin-fixed, paraffin embedded 
(FFPE) sample.  
Proteins become cross-linked, allowing only in situ methods based on 
immunohistochemistry or immunoflourescence. These methods are limited by inability to 
quantify protein levels, high requirement of rare tissue in the case of archival DCIS, and 
high labor requirement when scaled to large studies. However, tissue microarrays 
(TMAs) have been employed with increasing frequency to allow mass examination of 
samples across multiple markers with small amounts of tissue. The development of 
automated quantitative analysis (AQUA!) by Dr. David Rimm at Yale University 
School of Medicine82 has expanded on this technology to allow quantification of protein 
levels and statistical clustering of samples by these results.  
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DNA and RNA are both fragmented and chemically modified by the heating and 
treatment of the fixation and embedding process in archival specimens. FFPE RNA is 
especially vulnerable due to endogenous ribonucleases and was long considered 
unusable. Like with protein analysis, RNA harvesting and analysis has evolved, and 
FFPE tissue has been used for expression analysis by both real time polymerase chain 
reaction (RT-PCR) and microarray.83-85 The factors most affecting successful use seem to 
be time to fixation, time of storage, amount of tissue used, and extraction technique.86 
Even with these optimized, past microarray studies with FFPE samples in DCIS have 
been forced to rely on amplification of RNA, specifically via T7-primers, to generate 
requisite template amounts. This method results in attachment of a T7 sequence to 
amplified RNA (aRNA). Unfortunately, these sequences on the aRNAs have the potential 
to subsequently hybridize to complementary motifs on microarray probes, resulting in 
non-specific signal. This has been seen to occur in up to 1-9% of probes on some arrays.87 
New microarray technology has attempted address these and other problems in using 
FFPE RNA. In our study we will use one such approach developed by Illumina, the 
cDNA mediated Annealing, Selection, extension and Ligation (DASL) array. DASL uses 
random priming to form cDNA followed by oligo hybridization and advertises higher 
sensitivity for low RNA input. It thus avoids both amplification bias and dependence on 
an intact poly-A tail for oligo-d(T) priming. Further, DASL probes recognize small (<50 
base pair) regions within genes and produce uniform 100 base pair amplicons, which 
should reduce bias against transcripts more prone to degradation. With these and other 
features, the use of unamplified RNA in global expression analysis is now potentially 
feasible.83   
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Though DNA is sturdier, it too requires special adjustments for use in larger scale 
studies such as comparative genomic hybridization. The high quality DNA required of 
current CGH analyses in particular have limited past work on allelic imbalances to a 
combination of FISH and select LOH analysis, which lacks high resolution and 
scalability.86 Our collaborator Dr. Jim Hicks at Cold Spring Harbor is pioneering 
techniques for the use of FFPE DNA in CGH.  
Mass Mutation Screening 
 Notable advances have been made in the field of mutation re-sequencing which 
are especially valuable in setting of the challenges facing DCIS work. As a neoplastic 
process, DCIS evolution is driven by inactivating mutations in tumor suppressors and 
activating mutations in proto-oncogenes, which select for growth advantage.  
Recently, landmark studies using unbiased sequencing of breast and colon cancer 
genomes revealed a number of novel candidate “cancer genes,” most of which had no 
previous connection to malignant diseases.88,89 These studies have the potential to reveal 
new therapeutic targets and prognostic markers. Moreover, they have been followed up 
with attempts to replicate the scale of sequencing using new high-throughput 
technologies that promise cost-effective, personalized mutation sequencing.90,91 Still, 
available sequencing platforms are unable at present to provide coverage of all known 
genes. Development of an interim strategy focuses on directing the high-throughput 
platform sequencing to high priority targets, namely gene exons. In this method, a high-
density microarray is used to hybridize and thus ‘capture’ coding exons of interest for 
sequencing. This has described with some success in experimental runs on breast and 
colorectal carcinomas.92  
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The study of DCIS transition is particularly suited to high-throughput mutation re-
sequencing analyses since a) little tissue and thus DNA is available for analysis, b) 
though a genetic alteration almost certainly drives the acquirement of invasiveness in 
DCIS, no known causative mutations have yet been consistently identified, and c) 
extension of large scale mutation profiling to a common lesion like DCIS needs to be 
done in a cost conscious manner. Only prospective, fresh tissue samples can be utilized 
due to technical requirements. Even with prospective specimens, core biopsies often are 
all that can be sacrificed from diagnostic pathology on the specimen. In this setting, new 
methods of growing primary lines briefly before molecular analyses have been 
introduced, such as the mammosphere.93,94  
Summary of Rationale 
 Widespread screening mammography has led both to earlier detection of breast 
cancer and increased diagnosis of precursor lesions to invasive disease. DCIS is the most 
prominent of these for its large epidemiological footprint and its biological importance as 
a direct precursor to IBC. Though DCIS in itself is not capable of metastasis, the 
increased risk for invasive disease that it incurs has prompted empirical treatment 
measures consisting of surgery, radiation, plus/minus hormonal therapy. However, it is 
also known that not all DCIS will progress to invasive disease. Moreover, current 
therapies do not come without their own morbidities and costs.  
 Thus, great effort has gone towards producing predictive methods for assessing 
which DCIS lesions will go onto become invasive and which will not following 
observation or therapy. Unfortunately, no histological or demographic criteria have been 
able to affect treatment stratification. This is paired with a lack of fundamental biologic 
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understanding of DCIS evolution. In this setting, molecular approaches to 
characterization of the transition become attractive for offering a more in depth analysis 




There are biologically distinct populations of DCIS that possess different prognoses for 
recurrence and progression to invasiveness and which can be distinguished at the time of 
diagnosis based on molecular markers. Comparative study of DCIS lesions as they evolve 
may elucidate these markers and provide predictive tools for clinicians treating DCIS. 
The utilization and validation of newly developed technologies may facilitate such study.  
Design 
In testing the hypothesis, the overall work encapsulating this study divides into two 
phases. As previously discussed, ‘ideal’ research designs for study of DCIS recurrence 
have been limited previously by technical capabilities. Thus, the first phase, presented 
here, is designed to pilot new molecular assays for use on the type and amount of DCIS 
specimen material expected to be available for analysis. The target parameters for assays 
and tissue type are guided by the second phase of the study in which the actual analysis 
of DCIS heterogeneity occurs as tentatively projected here: 
• Compare molecular profiles of archival DCIS that did recur to DCIS that did not 
recur. 
• Compare archival DCIS that recurred as DCIS to DCIS that recurred as IBC. 
• Compare newly diagnosed DCIS without associated invasion to DCIS with associated 
invasion. 




These proposed goals call for the ability to conduct studies on two categories of 
tissue: retrospective and prospective. Retrospectively, molecular assays able to utilize 
FFPE material are needed for application to archival DCIS specimens excised by 
lumpectomy and paired with clinical follow up. This allows comparison of DCIS that did 
not recur with DCIS that does recur as a whole and by type: invasive or in situ. Further, 
since LCM will be used to selectively gather neoplastic epithelium from rare archival 
DCIS specimens, the techniques will need to be able to use very small amounts of 
substrate. Prospectively, assays capable of using small amounts of fresh material from 
core biopsy samples of DCIS are needed. Thus, our aims for this study are as follows: 
 
Aim 1: Pilot molecular analyses including microarray gene expression assay on archival 
LCM FFPE DCIS specimens. These will be paired with comparative genomic 
hybridization and tissue microarray pilots in FFPE being performed by Dr. Jim Hicks and 
Dr. David Rimm, respectively. 
Aim 2: Pilot selective high throughput sequencing technology using exon capture for 




Statement of Involvement in Experiment and Design 
The study was a multi-group collaborative at Yale University School of Medicine. Each 
section within the methods will indicate where investigators aside from the thesis 
candidate either performed or will perform work. The candidate specifically played a 
primary role in assessing the parameters for technical pilots and designing them. This 
involved developing and adapting protocols for the use of archival tissue for nucleic acid 
extraction and preparation and microarray gene expression analysis and for the use of 
fresh material for high-throughput capture sequencing.  
Case Selection 
 Procurement of specimens was overseen by Dr. Donald Lannin, Director of the 
Yale Breast Cancer Center, from patients treated there and from its tissue bank. Informed 
consent was obtained from patients at the time of tissue retrieval by resection or core 
biopsy. Archival specimens were initially prepared and stored as formalin-fixed, paraffin 
(FFPE) embedded blocks according to standard pathological protocols in use at the 
Center. Blocks selected by Dr. Lannin for use in the retrospective cohorts were stripped 
of identifying information. Diagnosis and histological features were verified by Dr. 
Veerle Bossuyt, a breast pathologist in the Department of Pathology (Yale University 
School of Medicine). The first cohort of FFPE blocks obtained for Aim 1 pilot work 
consisted of DCIS specimens with synchronous IDC. For the follow up studies making 
use of this work, 50 specimens of pure DCIS without recurrence after treatment with 
lumpectomy and/or radiation were first identified. Subsequently, 25 specimens of DCIS 
that recurred as in situ disease and 25 specimens of DCIS that recurred with invasive 
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disease were identified as controls. These controls were matched by Dr. Bossuyt to 
invasive specimens in pairs according to decade of diagnosis, age (within 5 years), tumor 
size (<2cm or >2cm), histological grade according to the DIN system, presence or 
absence of comedonecrosis, margin width, and treatment (+/- adjuvant radiation). Quality 
control on the specimens included review by Dr. Lannin of the cases selected for 
completeness of diagnostic workup and surgical approach. Further, the specimens used 
were extracted from a single institution repository and thus were all subjected to a 
consistent management approach such as the involved clinical oncology team and storage 
protocols.  
Prospective pilot trials for high-throughput sequencing utilized primary cell lines 
derived from primary lesions of malignant melanomas in conjunction with a study on 
metastatic melanoma. These lines were generated by the laboratory of Dr. Ruth Halaban 
and based on pathological specimens obtained through Dr. Mario Sznol in the 
Department of Medical Oncology at Yale University School of Medicine (Yale-New 
Haven Hospital). Identifying information was removed prior to work. 
Archival Specimen Preparation 
Certain analyses required extraction of nucleic acids from the specimens. In these cases, 
archival FFPE specimens of DCIS involved in Aims 1 were cut by Research Histology at 
Yale University School of Medicine into serial 5-µm or 10-µm sections using a 
microtome, which was treated with RNAseZap" (Ambion, Austin, TX) and rinsed with 
RNAse-free water. Deparaffinization of slices was conducted immediately prior to their 
use with storage in nitrogen chambers before this time. Using index H&E stained slides 
for discrimination for each block, Dr. Arun Gopinath in the Department of Pathology 
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performed laser microdissection (LCM) to isolate invasive, in situ, and normal cell 
populations as needed with the Leica LMD7000 (Leica Microsystems, Wetzlar, 
Germany). LCM use in breast cancer can reduce contaminating cell content to 0.6%.95 
The dissected tissue were collected in 40µl of proteinase K digestion buffer (Ambion) 
used directly or stored at -80°C in accordance with data showing these approaches as 
ideal for minimizing nucleic acid degradation.84 
FFPE Nucleic Acid Extraction 
 This study sought to apply advances in FFPE molecular analysis described in the 
introduction to the study of DCIS, which presents a particular challenge due to the small 
amounts of tissue for analysis available from an in situ lesion after LCM purification. 
Archival specimens that had been microdissected were put through a proprietary 
extraction process, the RecoverAll" Total Nucleic Acid Isolation Kit for FFPE 
(AM1975, Ambion), in order to obtain both RNA and DNA simultaneously from serial 
slices of the same case. The modified protocol employed began with standard protease 
digestion (proteinase K) followed by high-salt washes on a silicon bead column and 
nuclease digestion of the unwanted nucleic acid component (i.e. DNAse for RNA 
extraction). 60-µL nuclease-free water was used to elute the RNA or DNA into nuclease-
free tubes. The recovered nucleic acid was then vacuum dried and re-dissolved in 5µL of 
nuclease-free water. Quantification was accomplished by spectrometry on the NanoDrop-
1000 (Thermo Scientific, Wilmington, DE) per manufacturer protocol. RNA samples 
were stored at -80°C, and DNA samples were stored at -20°C. One aspect of the pilot 
investigations employed a heating protocol, specifically 5 minutes at 70°C, to remove 
chemical modifications (mono-methyolol: –CH2OH) from RNA.
96 RNA integrity was 
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quality tested by Bioanalyzer 2100 system (Agilent, Palo Alto, CA) at the Keck facilities. 
RT-PCR of (glyceraldehyde 3-phosphate dehydrogenase) GAPDH, as described below, 
was conducted prior to use in molecular analyses as a further quality check.  
RT-PCR 
Experiment specific standard inputs, typically 100ng, of total RNA were reverse 
transcribed into cDNA libraries using the iScript system (Bio-Rad, Hercules, CA), which 
contains both random and oligo-T primers suited to degraded FFPE RNA. Standard 
aliquots of 1:10 dilutions of these cDNA were analyzed by RT-PCR using an iCycler 
(Bio-Rad) system according to manufacturer’s instructions. All probes used were 
TaqMan gene expression assays (Applied Biosystems Inc., Foster City, CA), which are 
proprietary 5’ nuclease assays with standard annealing temperature of 60°C (Appendix 
1).  Relative quantification of gene expression was performed in triplicate reactions 
normalized to GAPDH (Hs99999905_m1, Applied Biosystems Inc.). Negative controls 
consisted of no RNA input into reverse transcription as a control against genomic DNA 
contamination on extraction and no cDNA input. Positive controls were derived from 
both MCF7 cell line RNA and DNA.  
DASL Oligonucleotide Microarray 
The 96-well whole transcriptome DASL microarray by Illumina (San Diego, CA) was the 
chosen platform for its high sensitivity requiring small input amount and specific probe 
design for degraded FFPE RNA. All RNA used was functionally tested by RT-PCR of 
GAPDH (Hs99999905_m1, Applied Biosystems Inc.) prior to usage with Ct value <35 
used as a threshold for microarray application. In the study pilots, deliberate amounts of 
input RNA were loaded according to stated design in optimizing the array for our work. 
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For ongoing and future analyses, 450ng of RNA are loaded in 5 µL volumes. This 
benefitted from the aid of Kyle Halligan and Dr. Kimberly Lezon-Geyda in the laboratory 
of Dr. Lindsay Harris with whom we shared arrays in our pilots. Each array is run using 
the Illumina Golden Gate Assay Protocol at the W.M. Keck Facility, a biotechnology 
core associated with Yale University School of Medicine, under the supervision of its 
microarray resource director Dr. Shrikant Mane. Images scanned by BeadArray Reader 
(Illumina) at the Keck are visually inspected and evaluated using the associated 
BeadScan software for image processing and intensity data extraction; BeadStudio 
(Illumina) enables export of this data. The lumiR 2.8.0 (Open Source, Pan Du, Chicago, 
IL) package software is employed by Drs. Tuck and Schulz to analyze the data. Probe 
IDs were mapped to genes using lumiHumanAll annotation package. Background was 
adjusted to force all values to be positive, log2 transformed, and quantile normalized. 
Unsupervised, hierarchical clustering is performed on all DCIS specimens to discover a) 
if they cluster together vs. invasive specimens in pilot work and b) if they cluster together 
within same case replicates in the pilots. For this, all expression values were standardized 
to have a constant mean and scaled root-mean-square. Only probes of variance >0.1 were 
analyzed. The Euclidian distance matrix was then calculated, and clustering analysis was 
performed using the average agglomeration method. Heat maps were produced with 
default R Euclidean clustering while sample relation dendogram was produced using the 
lumi R default Multi-Dimensional Scaling algorithm. Supervised clustering will be 
performed in the follow up experiments to assess for differentially expressed gene 
transcripts in the proposed comparison cohorts. 
FFPE DNA Sequencing 
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FFPE DNA is amplified via Sanger PCR method with Invitrogen (Carlsbad, CA) primers 
for selected gene exons stated in each experiment with annealing temperatures 
empirically assessed by gradient protocols (Appendix 2). PCR was performed using the 
PfuUltra HF polymerase and kit (formerly Stratagene, now Agilent). After verification of 
amplicon generation by gel electrophoresis, amplified DNA is purified using a DNA PCR 
Purification Kit (Qiagen, Valencia, CA) and sequenced at the Keck Facility on Applied 
Biosystems 3730 capillary instruments using fluorescently-labelled dideoxynucleotides 
(Big Dye Terminations) and Taq FS DNA Polymerase in a thermal cycling protocol. 
Electrophoretic data is returned standard file sequence for analysis on 4Peaks software 
(Mekentosj, Aalsmeer, The Netherlands). 
Exon Capture High-Throughput Sequencing 
Design: The pilot work aimed to use hybridization for capture of exons from selected 
genes of interest. The gene list for this design was generated based on a review of several 
databases that have identified genes of interest in cancer generally and in breast cancer 
specifically that are known to harbor mutations. Genes only having alterations in 
amplification or expression, such as Epidermal Growth Factor Receptor or Estrogen 
Receptor, were not included as the capture sequencing only detects sequence alterations 
within a gene copy. The selected 874 genes were taken from the Sanger Welcome 
Database (http://www.sanger.ac.uk/genetics/CGP), the protein kinase family,97,98 the 
tyrosine phosphatases,99 the lipid kinases,100 the Ras family,101 the cancer candidate genes 
in the seminal work of Wood et al.,89 and several associated labs (Appendix 3). Primary 
sequence for these genes was extracted from Build 36.1 of the NCBI’s genome 
annotation using the UCSC Table Browser (http://genome.ucsc.edu); this track on the 
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Table Browser is also known as hg18 and released on March 2006. Exons from these 
sequences less than 250 bases in length were buffered in both the 5’ and 3’ directions to 
250 base pairs minimum for use as targets for probe design. The locations of these 
sequences were submitted to the tiling array design team at Roche NimbleGen (Madison, 
WI) for generation of overlapping 60mer oligo probes on a 385k feature array; the total 
coverage was 4.86 Mbp with probe spacing minimized. The sequence search and 
alignment hash algorithm (SSAHA) was used to generate unique probes allowing up to 5 
indels for improved specificity of capture. The specifics of the probe design process 
beyond these including masking and consolidation algorithms is proprietary to 
NimbleGen but is based on their technical reports.92 However, post-hoc analysis using 
ELAND-extended program assessed quality of design through measurement of number of 
probes per targeted RefSeq transcript, number of probes per targeted exon, and 
uniqueness of probes as measured by number of transcripts targeted by a probe 
Capture: High quality gDNA from primary cell lines (YUMINE from melanoma 
associated fibroblasts, YUHEF from melanoma) was obtained from the laboratory of Dr. 
Ruth Halaban through ethanol precipitation with quality checks by Nano-Drop A260/280 
ratio, gel electrophoresis showing high molecular weight bands, and RT-PCR of 
GAPDH. The following steps in preparation and hybridization of gDNA to array were 
aided by Rajini Haraksingh and performed according to the NimbleGen Array User’s 
Guide for Sequence Capture Array Delivery 1.0 with added quality control steps as 
noted. 20µg of DNA for each sample was randomly fragmented through sonication using 
a Diagenode Biorupter (Sparta, NJ) to a median size of ~500 base pairs, which was 
confirmed visually by gel electrophoresis and Bioanalyzer. Blunt end generation with the 
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Klenow fragment of T4 DNA polymerase (NEB) and phosphorylation with T4 
polynucleotide kinase (NEB) followed during the ‘polishing’ reaction. gSel3 oligo (5’ – 
CTC GAG AAT TCT GGA TCC TC – 3’) was used to create linkers which were 
attached to the DNA fragments. Small fragments were removed according to 
manufacturer protocol with Dynal (NimbleGen) and Bioanalyzer again used to confirm. 
After confirmation of appropriate yield with LM-PCR, hybridization was carried out per 
manufacturer protocol on a NimbleGen Hybridization System (MAUI) with active 
mixing in 1x hybridization buffer for ~64 hours at 42°C. The array was then subjected to 
washing 3 times each with Stringent Wash Buffer 1x (NimbleGen) and Wash Buffers I, 
II, and III (NimbleGen). Hybridized, or ‘captured,’ gDNA was then eluted with 2x 425µL 
of water at 95°C. The samples were then lyophilized and resuspended in water. Linker-
mediated PCR (LM-PCR) was then performed comparing pre- and post-capture samples. 
These samples were further evaluated by RT-PCR as a preliminary surrogate of 
efficiency of capture. 
Sequencing: Illumina’s Solexa platform (San Diego, CA) was used to generate sequence 
data on the captured DNA. This platform relies on fluorophore-coded synthesis of DNA 
templates that are bound to a solid phase support. Synthesis from each fragment is 
enabled by adjacent oligonucleotide primers, which are anchored across the support. 
Sequences of up to 35 base pairs (23 base pairs after excluding primer sequence) can be 
produced from each fragment’s ‘colony’ in a massively parallel manner. This information 
is then interpreted using bioinformatics to align individual reads to the genome and 
generate continuous sequence information.  
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Sequencing requires compatible linkers known as 1G adaptors to be affixed to the 
ends of the eluted, ‘capture’ fragments of mean size 200 base pairs for ideal efficiency. 
The capture process, however, was most effective at 500 base pair sizes and involved the 
use of non-compatible gSel3 linkers. Sonication with the Biorupter again was employed 
to generate smaller fragments with linker-free ends. These free ends were blunted and 
phosphorylated with the Klenow fragment of T4 DNA polymerase (NEB) and T4 
polynucleotide kinase (NEB), respectively, with subsequent 3’ adenylation with Klenow 
fragment per Illumina protocol. With each step, DNA was purified with QIAquick PCR 
Purification Kit and Protocol (Qiagen). LigaFast (Promega #M8221) was used with the 
Illumina adaptor mix to rapidly affix linkers to the adenylated ends. The fragments were 
gel purified on a 2% Invitrogen gel (#G5018-02) with a Qiagen Gel Extraction Kit and 
then amplified with PCR using a Phusion DNA polymerase kit (Finnzymes) and adaptor-
appropriate primers 1.1 and 2.1 (Illumina). After spin column purification of the PCR 
product (Qiagen), the captured DNA was quantified by NanoDrop and inputted at 
10ng/µL into a single Solexa flow cell lane. Flow cell hybridization, priming, and pyro-
sequencing by base incorporation were carried out by the laboratory of Dr. Michael 
Snyder on an Illumina 1G analyzer.  
Read mapping and coverage analysis: Project collaborators Dr. Michael Krauthammer 
and Sebastian Szpakowski, a Ph.D candidate, performed analyses of the sequencing data 
as generally described here. Probe sequence targets for the NimbleGen array were 
mapped to the human genome’s hg18 annotation using BLAT. This was done to assess 
the genomic coverage of the custom microarray. Subsequently, the reads generated by the 
Solexa (Illumina) sequencer runs were processed for quality and uniqueness using the 
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ELAND-extended analysis pipeline. Only the high quality reads that had no mismatches 
and uniquely mapped to the human genome were retained for further analysis. The BLAT 
and ELAND results were then aligned, allowing assessment of the number of reads per 
probe. A “false image” of the microarray was generated where the reads-per-probe count 
could be matched to physical locations on the arrays and thereby allow a quality check 
across its surface. Quantitative and visual assessment of any such ‘smudging’ effect was 
allowed by the R package SmudgeKit, which generates contours according to signal 
intensity and highlights outlier regions representative of potential spatial artifact. The 
alignment of probe sequence and reads generated estimation of several metrics of 
efficacy of array design and capture sequencing. The most important include coverage for 
the selected gene exons and specificity. This was assessed in terms of reads associated 
with a) the target exon regions and b) each base pair of the target exons. Correlation of 
read count with exon length was also measured given the number of probes likely 
increased with targeted sequence length. Specificity was calculated by comparison of the 
reads covering intended targets and the total number of reads generated uniquely 
mapping to the genome. In contrast to other studies, no calculation was made of number 
of reads mapping to regions near targeted sequence that might represent positive capture 
without target sequence generation. This conceptually would measure the captured DNA 
fragments inputted into sequencing which contain internal targeted regions allowing 




The goal of this study was a) to pilot new technologies for novel investigations of 
tumorigenesis in DCIS and cancer generally and b) to apply these technologies to 
molecular characterization of DCIS progression to invasive disease. Due to limitations of 
time and the need to present the latter data as a completed whole for coherency, only the 
pilot data is available here though the methodology for all work intended was described. 
These pilots broadly can be classified into those directed at enabling molecular analyses 
of archival FFPE tissue and those directed at extending sequencing abilities from small 
prospective specimens. 
Molecular analysis of archival tissues 
Archival tissue, predominately stored as FFPE blocks, are well suited to tumorigenesis 
studies in DCIS given their associated clinical follow up and the difficulty of access to 
prospective tissue given diagnostic requirements. Here we describe pilot studies on the 
use of nucleic acids from FFPE DCIS samples across varying ages in regards to 
extraction, enhancement protocols, exon sequencing, and expression analyses. 
Tissue selection, LCM, and nucleic acid extraction 
Pilot DCIS specimens of varying grades and histologic features were selected from the 
same tissue bank as the planned study (Yale Breast Cancer Center, New Haven, CT). All 
tissue was obtained following lumpectomy without prior systemic treatment.  A total of 8 
FFPE specimens of DCIS were selected, including 2 from the same patient to allow for 
assessment of assay reproducibility across specimens (Table 1). All came from patients 
with co-existing DCIS and IDC that were hormone receptor negative but not HER2/neu 
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amplified. After confirmation of diagnosis and histologic characteristics by a breast 
pathologist, each specimen was sliced into 10 µm sections and underwent laser 
microdissection for neoplastic epithelium. 
Table 1. DCIS Case Description. Cases are organized and named 
according to patient source and age of storage. *Cases 1.1 and 1.2 
were derived from separate blocks of the same patient tumor. 




1 1.1* 2 N1, N2, N3 
1 1.2* 2 N4 
2 2 2 N5 
3 3 3 - 
4 4 9 - 
5 5 19 - 
6 6 19 - 
7 7 29 - 
 
 This approach and nucleic acid extraction protocols were first established on non-
study tissue. The pilot study tissues were utilized to describe the relationship of extraction 
yield to tissue input (Figure 3). For this assessment, individual extractions of nucleic 
acids were paired with data from laser mirodissection on the total surface area of ducts 
collected. 117 RNA extractions, 29 DNA extractions, and 9 simultaneous extractions of 
RNA and DNA from microdissected material from a single side were used. Simultaneous 
extraction produced unreliable, low yields and were excluded from analysis (data not 
shown). Ratios of the RNA and DNA amounts extracted to the surface area collected 
were then calculated for each specimen based on initial index slices. Yields varied 
significantly between specimens from 2007 and 1990 (Figure 3c). However, yields also 
seemed to vary between other specimens of the same approximate age, suggesting age 
was not the only factor affecting yields. For instance, the specimen from patient 3 
produced far less RNA per area dissected than specimens from patient 1 or 2, which were 
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only a year ‘younger.’ The nucleic acid yield of a specimen was thus extrapolated from 
initial extractions on its tissue block, guiding further dissection as needed. This approach 
was important for preserving the rest of the specimen, which would ideally be used for in 
situ protein expression analysis by TMA. Spectroscopy based quantification (NanoDrop) 
also allowed initial quality assessment of all nucleic acids by A260/A280 ratio. Further, 
all RNA was assessed by Bioanalyzer with a RNA integrity number (RIN) >1.9 chosen as 
a conservative minimum threshold for further use. 
 
RNA Expression Analysis 
The goal of the pilot for RNA expression analysis was to validate a reproducible genome 
wide expression analysis platform using unamplified, FFPE RNA from DCIS neoplastic 
Figure 3. Analysis of nucleic acid extraction 
yields. a) Yield by case and age of specimen. 
b) Ratio of yield to surface area. C) Ratio of 
yield to surface area grouped by year of 
specimen harvest. Multiple specimens existed 
for the years 1990 (patients 1 and 2) and 2007 
(patients 5 and 6). Standard deviations are 
indicated for each metric. No DNA extractions 
were performed on Case 1.1 
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epithelium. After initial quantification and quality assessment, qualifying RNA extracts 
from the pilot study specimens were subjected to a heating protocol, which aimed to 
remove chemical modifications from the storage process. A representative example of the 
benefit of this heating protocol on signal detection in RT-PCR, a surrogate for signal 
detection on microarray, is shown in Figure 4 . RNA samples were then assessed for 
signal detection by RT-PCR of a standard probe (GAPDH Hs99999905_m1, ABI). A Ct 
value <35 was required for use on microarray. A selection of samples that had passed the 
quality parameters of spectroscopy, Bioanalyzer, and RT-PCR then were used to pilot the 
use of unamplified FFPE RNA on the DASL (Illumina) whole genome microarray.  
 
Several variables were assessed by comparison in the pilot design. First, input 
RNA amount was varied to assess for a) the minimum required amount for reliable signal 
Figure 4. Enhancement of baseline expression signal in RT-PCR by RNA heating 
protocol. Representative examples of enhancement here are seen across two different 
probes for GAPDH cDNA. Experiments were done in triplicate and shown as fold change 
versus primer 1 baseline signal for GAPDH at a constant 54ng RNA input with identical 
cDNA aliquots into RT-PCR. Standard deviations are shown. 
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detection and b) whether signal data was influenced by input and not compensated for by 
internal array controls as advertised. Though the indicated minimum for RNA input on 
the DASL arrays used was 50 ng, it was unknown how the degradation level of FFPE 
RNA affected this requirement. At the same time, the minimum RNA required was likely 
to not always come from a laser microdissected single slide. Thus, two different methods 
for pooling extractions from separate slides of a tissue block were assessed for best signal 
detection. One involved combining samples prior to the extraction protocol, while the 
second combined specimens after separate extraction. Lastly, the use of extractions from 
separate blocks of the same specimen assessed for reproducibility of expression data on 
this platform. As a positive control, the samples were run alongside RNA extractions 
from FFPE cores of recent (2009) invasive breast disease that had successfully produced 
data in the past. This control also provided a set of tumors with an array of expression 
profiles within which the pilot DCIS samples could undergo clustering analysis. 
Unsupervised hierarchical clustering was generated by lumiR default Multi-Dimensional 
Scaling algorithm to produce a dendogram of the interrelatedness of the DCIS samples 
and the invasive tumors run (Figure 5).  
First, these results demonstrated that unamplified, FFPE derived RNA from DCIS 
specimens could be used to generate whole genome expression data. Secondly, these 
results seemed reproducible. 3 of the 4 samples from the same patient (patient 1), N1, 2, 
and 4, which came from different blocks (1.1 and 1.2), grouped together closely. The 
outlier sample, N3, differed in preparation, using both a higher input of RNA (650 ng) 
and a contrasting post-extraction pooling method. N5, like N3, was RNA pooled post-
extraction. Both N3 (Figure 6) and N5 had a low signal detection rate, though only N3 
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surpassed the threshold for inclusion in analysis. N5 did not meet the threshold signal 
detection and was excluded from clustering dendograms. The detectable DCIS samples, 
excepting N3, grouped together, distinct from the vast majority of the invasive 
specimens. Only one invasive specimen grouped with the DCIS sub-cluster. N6, from 
patient 3, did however lie outside the patient 1 sub-group of N1, 2, and 4 as expected 
given the different tumors of their origin.  
 
 
Since the pilot DASL was aimed primarily at evaluating feasibility of producing 
reproducible signal and clustering results, it was not deemed necessary to mass validate 
Figure 5. Hierarchical clustering dendogram of gene expression in FFPE DCIS and 
invasive specimens on DASL (Illumina) whole genome microarray. A table indicates 
the coding of the DCIS samples used, of which all but N5 produced threshold signal data. 
Samples beginning with ‘N’ represent DCIS specimens run alongside all other named 
invasive specimens; these are enlarged for visualization. Clustering was performed as 
described based on an ‘intrinsic’ gene set of 8,751 genes with standard deviation relative 
to mean > 0.1. 
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gene transcript expression profiles by RT-PCR. However, select validations were 
performed with a representative example of this effort demonstrating high levels of 
ErbB2 transcript by RT-PCR in agreement with the array data (Figure 7).   
 
 
DNA mutation re-sequencing by PCR pilot 
DNA is considered more resistant to degradation by the formalin fixation and paraffin 












Figure 7. Representative 
validation of array 
results with RT-PCR 
using the ERBB2 
transcript probe. RT-
PCR was carried out 
using identical inputs of 
RNA and cDNA in 
triplicate and shown as 
fold change normalized to 
GAPDH. Results are 
aligned with heat map 
representation of results 
from array against control 
MCF7 line with known 
low ERBB2 expression. 
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feasibility and validity of the sequencing results from these specimens prompted a pilot 
study. The pilot specifically assessed the length of exon reads routinely possible with 
FFPE DNA derived from laser microdissected DCIS. Primer sets (Invitrogen) for ErbB4 
(Appendix 2), which had been previously validated and used in the laboratory, were 
used. Amplicons of 186 base pairs from exon 20 of ErbB4 were routinely sequenced by 
Sanger PCR method and verified on by BLAT (UCSC Genome Browser). The redundant 
use of both forward and reverse strand primers allowed high quality, reproducible, and 
minimal error sequencing throughout the amplicon (data not shown due). Use of a single 
strand primer tended, in contrast, to produce uncertainty at the end of a read 
corresponding to the 5’ or 3’ end of exon.  
Selective high-throughput sequencing 
Prospective studies will require validated techniques for maximizing molecular analysis 
of small amounts of tissue. Selective mass sequencing from small inputs has been 
suggested as a possibility in the literature.92 The pilot studies here describe efforts to 
validate a custom array based capture method for selective high-throughput sequencing 
of breast cancer and melanoma related genes (Appendix 3). 
Design 
Design of the capture array was performed on a NimbleGen 385K feature array, as 
described in the methodology, by Sebastian Szpakowski and Dr. Michael Krauthammer. 
Quality assessment of probe design was conducted using ELAND-extended software 
across several metrics shown in histogram format (Figure 8). The microarray contains 
381,034 probes designed for human genes. Based on the overlap of BLAT mapping of 
probe sequences and known gene transcript sequences (RefSeq transcripts), 372,143 
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probes were found to overlap with at least one Refseq transcript. This includes probes 
that align to a transcript ideally or with 1 mismatch. Overall the probes were mapped to 
2,273 Refseq transcripts and their 22,492 exons. Measurement of specificity by the 
number of transcripts sampled by each probe revealed that the majority of probes aligned 
to a unique transcript region. A significant number also aligned to more than one 
transcript, however, few aligned to more than 2.  Coverage of target regions was 
measured by the number of probes assigned to each transcript, which varied widely. The 
majority of transcript features contained at least several probes. Within a targeted 




Figure 8. Design analysis by ELAND-extended of capture array probes. All analysis done 
by Krauthammer lab of capture sequencing performed by thesis candidate and collaborators as 
indicated. a) Number of transcripts in RefSeq database sampled by probe based on sequence. b) 
Number of probes assigned to each targeted exon. c) Number of probes assigned to each target 
RefSeq gene transcript. 
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Capture 
Fragmented DNA from two melanoma lines, YUMINE and YUHEF, were hybridized to 
the custom array and the post-capture DNA sequenced. Capture efficiency across the 
arrays was first assessed for performance by alignment of sequence reads to the physical 
location of corresponding targeting probes on the array. This allowed visual inspection 
for differences in signal intensity, representing sequence reads, according to a probe’s 
location on the array that might be suggestive of a ‘smudge’ artifact during the capture. 
Contour plots of signal intensity across the arrays demonstrated sufficiently 
homoegeneous capture to rule out major smudge artifacts (Figure 9).  However, 
comparison of the “false images” of signal intensity according to physical probe location 











Further characterization of the capture focused on specificity and sensitivity. 
While the microarray targeted 22,492 exons, the sequence reads aligned to 7,297 of these 
exons (32.4%) in the YUHEF cell line and to 5,549 of these exons (24.7%) in the 
YUMINE cell line. The relationship between number of reads per exon and exon length 
was characterized as well (Figure 10). However, the association was weak with a 
correlation coefficient in the YUHEF capture of 0.43 and in the YUMINE capture of 
0.33. Analysis of the relationship of number of probes designed per exon to the number 
of reads obtained from sequencing yielded higher correlations of 0.52 and 0.4 for 
YUHEF and YUMINE, respectively. In addition to the 22,492 targeted exons, the 
YUHEF capture sampled 20,448 additional exons, and the YUMINE capture sampled 
7,399 additional exons. This non-specific sampling was shared amongst the two captures 
in only 1,334 exons. Specificity of reads thus was calculated as 26.3% in YUHEF and 




unique sequence reads align to 828 targeted genes (94.7% of the full 874 gene set) in the 
YUHEF capture, and 203,965 reads aligned to 815 genes (93.2%) in YUMINE capture. 
Overall, YUHEF’s 1,842,511 reads and YUMINE’s 1,539,151 reads aligned to a total of 
14,790 genes each. While the average read coverage for the 14,790 known human genes 
was 99.8 reads/gene in YUHEF and 107.4 reads/gene in YUMINE, the average read 
count for the specifically targeted 874 genes was higher at 261.3 reads/gene and 243.4 
reads/gene for YUHEF and YUMINE, respectively. 
 
Visual representations of successful capture examples were generated using the 
Integrated Genome Browser (Figure 11). A list of ‘indel’ and single nucleotide sequence 
alterations was produced by comparison of sequences with multiple reads to BLAT 
aligned regions (data not shown). Validation by Sanger PCR sequencing is pending. 
Furthermore, comparison to single nucleotide polymorphism (SNP) databanks has not yet 
been performed; thus, these candidate mutation lists are unrefined. More important again 
is the feasibility endpoint of this pilot, which was achieved.  
Figure 11. Visual 
representation of example 
of capture sequencing using 
RAP1GAP gene exons.  
Integrated Genome Browser 
was used to align sequence 
‘hits’ from the YUMINE and 
YUHEF captures to genomic 
coordinates. Comparison can 
thus be made to the 
coordinates of target exons 
(green), here showing poor 




The study of tumorigenesis requires information on the evolution of a lesion in 
vivo, which has presented barriers to effective molecular analysis of progression in 
diseases like DCIS. Prospective studies incur large time investments and are inhibited by 
the difficulty with accessing fresh tissue due to diagnostic needs. Various cross-sectional 
and retrospective approaches have been utilized in an attempt to circumvent prospective 
study. However, each thus far contained confounding design issues due to technical 
limitations in studying archival tissue. Mainly, none have been able to properly evaluate a 
given lesion’s propensity for recurrence or progression, which is the key prognostic 
question at time of diagnosis. The goals of the overall study were to pilot technologies 
that would overcome limitations in past approaches to study of DCIS with the intent of 
applying them to the investigation of DCIS progression as laid out in the objectives. Our 
pilot work marked technical advances in a) the use of retrospective FFPE tissue for 
molecular analyses and b) the use of small amounts of DNA input for selective high-
throughput gene re-sequencing. Further, this work is paired with information from pilot 
studies from collaborators on CGH and quantitative TMAs in FFPE material that will 
allow comprehensive analysis of archival and prospective DCIS specimens. Our results 
will be discussed here in terms of methodology recommendations for ongoing future 
study objectives and implications for tumorigenesis study generally.  
Archival tissue analysis in DCIS 
The main body of material that would allow improved retrospective cohort 
designs, archival FFPE tissue with clinical follow up, has long been considered 
inaccessible to molecular characterization. In our pilot work on archival DCIS samples, 
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we demonstrated that laser microdissected neoplastic DCIS epithelium could be used 
successfully in microarray gene expression analysis and Sanger PCR based exon 
resequencing.  
The microarray pilot assessed feasibility, input amounts, RNA pooling 
methodology, and reproducibility of results across duplicates from different specimen 
blocks of the same patient. Comparison of signal data from our DCIS samples to signal 
data of the invasive specimens indicates the majority of our samples produced 
interpretable data. Conversely, our ‘failed’ sample, N5, has the same poor signal 
qualities, namely low detection rate (Figure 6), of poor performance invasive specimens.  
On hierarchal clustering, the grouping of most DCIS specimens together distinct from the 
unrelated invasive tumors is consistent with expectations given biologic differences. 
More importantly, the close grouping of 75% of the 4 samples from patient 1 regardless 
of tissue block source indicates that expression data was reproducible within a tumor. N3, 
the outlier sample from patient 1, may represent a limitation in the technology’s ability to 
produce reproducible data or a statistical variance given the low number of samples used. 
However, the poor signal detection rate of N3 suggests that the gene expression 
differences might be due to poorer performance from different preparation of the sample. 
Specifically, N3 was prepared with higher RNA input (650 ng) and a post-extraction 
method of pooling RNA from separate tissue slide extractions. N1 and N2, which 
represent differing RNA inputs from the same block of patient 1, nonetheless grouped 
together closely and shared pre-extraction RNA pooling methodology. Thus, it is more 
likely that N3’s failure to group with either the rest of the DCIS specimens or other 
samples from patient 1 is due to a different RNA pooling method rather than true gene 
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expression differences.  Indeed, the only other sample prepared with post-extraction 
pooling was N5, which failed to meet signal detection threshold. In light of this 
correlation, the failure of N5 and the aberrant expression data of N3 perhaps can be 
explained by the higher salt concentration in these samples. This would result from 
combination of separate extracts each containing a set amount of salt residue after high 
salt column isolation. This contrasts with pre-extraction pooling in which the combined 
tissues only are subjected to high salt washes once.  
The sum of these results and their implications thus suggests that a) laser 
microdissected neoplastic epithelium from DCIS FFPE can be used in the DASL 
microarray to produce expression data, b) the input RNA amount should be kept standard 
at either 450 ng or 225 ng, c) laser microdissected material for RNA isolation from a 
specimen should be pooled before extraction, and d) replicates are useful for assessing 
data reliability. The limitations of this work lie primarily in the low numbers used for 
comparisons. However, the pilots incur substantial costs due to pathologist time, 
technological expense of microarrays, and use of precious archival material. Given the 
endpoint of the pilot was to establish basic feasibility and a workflow, we thus deemed 
the uncertainty due to low statistical powering of the work to be acceptable.  
In contrast to previous work, we were able to avoid amplification of FFPE RNA 
prior to oligomer hybridization on the microarray. Instead, a combination of improved 
extraction technique, heating protocol for chemical modification removal96, and a new 
microarray platform was employed. Importantly, the DASL array hybridizes transcripts 
prior to amplification of cDNA.83,86 The reason for this approach is evidence that standard 
T7 based linear amplification of RNA arguably introduces bias into data.87 Conceptually, 
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this bias is likely even more significant in degraded, chemically modified RNA from 
FFPE specimens that are crucial to DCIS retrospective analyses. Like any manipulation 
of such RNA, T7 primer ligation is potentially biased towards certain transcripts which 
are better or worse substrates.  
 More broadly, the success of establishing a methodology workflow and platform 
for DCIS FFPE microarray based expression analysis allows the study’s key retrospective 
investigations regarding recurrence and progression to go forward.  Previous molecular 
studies on DCIS progression have used DCIS specimens co-existing with invasive 
disease in snapshot analyses as surrogates of progression.18,80 Part of the reason for this is 
to minimize inter-tumor variability background in assessing differences between DCIS 
and invasive disease. However, the main reason for doing so is the technical inability to 
utilize FFPE specimens for their analyses. These approaches have found few consistent 
differences between invasive disease and DCIS. Indeed, the two studies that analyzed 
FFPE DCIS after LCM isolation of neoplastic epithelium contain a marginal overlap of 
only 4 genes that are significant for differential expression. We hypothesize that study of 
pure DCIS specimens will reflect a more sensitive assay for detecting biologically 
distinct populations with different fates that might yield candidate markers of progression 
and/or recurrence.  
Nonetheless, in proceeding with our retrospective profiling studies, we will take 
note of concerns raised by our predecessors. Schuetz et al.80 has argued insightfully that 
the use of different microarray platforms likely contributes to the lack of overlap between 
gene candidate lists between their study and other studies on DCIS expression profiles. 
This same concern has plagued the comparison of data sets in gene expression profiling 
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for invasive breast cancer.102,103 Often, the “molecular signatures” generated by profiling 
studies exhibit little overlap and fail to validate on prospective analysis. Thus, we will 
take care to focus on the use of a single microarray platform we have validated for LCM 
FFPE RNA in DCIS and to validate any putative markers on both independent 
retrospective and prospective sets of DCIS. 
Less nuanced were our findings on the use of LCM FFPE DNA from DCIS for 
selected exon re-sequencing. Given our success on ~200 base pair reads, we may seek to 
perform limited sequencing analysis on candidate markers of DCIS progression and/or 
recurrence generated by the expression profiling studies.  
Selective high-throughput sequencing 
Prospective study of DCIS is made difficult technically by the diagnostic 
requirements on the excised tissue for ruling out invasive disease and for characterizing 
the histology. At the current time, a core biopsy of tissue after lumpectomy represents the 
total substrate of tissue available for analysis. In our study, we adapted the principles of 
exon capture-based selective sequencing to the need to extract large amounts of sequence 
data from small quantities of DNA that would be available from such core biopsies.  
Our custom array enriched for exons of genes implicated in breast cancer and 
melanoma (Appendix 3). This design both tested potential probes sets for future DCIS 
work and made any data gained from the pilot useful given the primary melanoma lines 
used were under active investigation. The use of the YUHEF and YUMINE primary 
melanoma cell lines in our pilot work simulated extractions from mammosphere primary 
lines of DCIS that are being developed in collaborator labs as means for enabling 
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prospective analysis of small biopsy samples in tumors. Specifically, these melanoma 
lines were early generation cultures from recently excised melanomas. 
  Our results confirmed the use of array-based enrichment for relatively selective 
sequencing on a Solexa (Illumina) platform. They also justify further development of the 
assay for use on our proposed prospective cohorts in the subsequent study phase. 
Nonetheless, the analysis of efficiency of our approach nonetheless revealed several areas 
for improvement. Foremost are improving the sensitivity of capture to increase the 
number of targeted exon reads and improving the specificity to eliminate wasted reads on 
non-target sequence. In comparison to technical paper reports of target exon coverage of 
78-99% depending on technique,92 our efficiencies (24.7% and 32.4% in YUMINE and 
YUHEF, respectively) were very low.  
Multiple limitations of experimental methodology rather than technical capability 
likely explain this discrepancy. First, our custom array was built around 60mer probes 
from NimbleGen rather than the 100mer capture array normally used for its larger and 
more specific hybridization potential. This produced a lower cost pilot array that also had 
the possibility of translating into a more cost efficient clinical application. Secondly, the 
sequence reads only come from 23 base pair end fragments of captured DNA segments 
that had a Solexa 1G-compatabile linker attached. This linker is a primer sequence 
attached to input DNA that allows priming of the flourophore based synthesis reactions 
that make up Solexa sequencing. As described in the methods, hybridization was carried 
out with non-compatible linkers on larger fragments that are optimal for capture.  This 
was followed by repeat fragmentation to create smaller fragments ideal for Solexa 
sequencing and free ends for attachment of Solexa 1G-compatabile linkers. Thus, only a 
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fraction of captured DNA had a free end with the appropriate linker for sequencing. This 
resulted in lower efficiency of selective sequencing overall than efficiency of target 
fragment capture itself.  
The large reduction in sensitivity and specificity likely due to these modifications 
will be addressed going forward in the continuing studies. Firstly, 100mer capture arrays 
have been procured with the probes validated on the pilot. Secondly, future capture 
hybridizations will be tailored to the planned sequencing platform according to fragment 
length and linker selection. In the case of Roche 454 sequencing,104 which advertises 
faithful reads of 200-400 base pairs, hybridization and sequencing can occur using 
fragment sizes ideal for capture (400-500 base pairs).  However, due to cost issues, 
Solexa is currently more viable. Solexa sequencing will require 1G compatible linkers to 
be attached to DNA fragments of <200 base pairs which will be used for capture and 
sequencing. Based on previous technical literature, the cost to capture efficiency of using 
shorter fragments should be more than compensated for by the increased sequencing 
efficiency.92 
Our pilot work did also produce sequence information on the melanoma lines we 
analyzed. Analysis of the sequence aligned to the genome generated a list of indels and 
mismatches. These data were not validated by Sanger sequencing. Moreover, it is likely 
many of these alterations represent SNPs or other changes not associated with tumor 
behavior. These analyses, however, were not the endpoint of the study, which instead 
focused on assessing capture efficiency rather than the fidelity of a proven sequencing 
platform.105 However, in future work, candidate mutations will be validated in such a 
manner. In summary, exploration of hybridization-based capture for selective high 
! BB!
throughput sequencing resulted in discrete recommendations for our future work on 


































































































































































































































































































Appendix 2. Invitrogen primers used for DNA sequencing. Primers 
include a 454 linker allowing Sanger pyrosequencing at an affiliated 
core facility as described. 
Gene Exon 
Amplicon Length 
(base pairs) Tm* Annealing T* 
ERBB4 18 123 67.3,66.9 54.9 
ERBB4 19 99 69.3,68.8   
ERBB4 20 186 68.7, 69.0 54.9 
ERBB4 21 156 68.3, 69.2 54.9 
ERBB4 22 76 68.1, 67.4 52.4 
ERBB4 23 147 65.0, 66.9 55.3 




Appendix 1. TaqMan Gene Expression Assays with reference ID (Applied 
Biosystems, Inc.). All assays run under protocol supplied with common annealing 
temperature of 60°C. IDs ending in -s1 refer to amplicon targets within an exon 
which will detect gDNA as well as cDNA. -m1 suffixes refer to amplicon targets 
spanning introns thus detecting only cDNA and not gDNA. -g1 refer to targets 
spanning small introns which may still detect gDNA. 














Appendix 3. Gene list used for exon capture design. Transcripts employed are listed according 
to RefSeq and/or CCDS accession number. UCSC Table Browser was used to generate exon 
coordinates based on these inputs. 874 genes are listed here derived from melanoma and breast 
cancer gene lists from the literature as described. 
Gene CCDS/Accession Name/Accession 
ABCA3 NM_001089 ATP-binding cassette, sub-family A (ABC1), member 3 
ABCB10 NM_012089 ATP-binding cassette, sub-family B (MDR/TAP), member 10  
ABCB8 NM_007188 ATP-binding cassette, sub-family B (MDR/TAP), member 8 
ABI1 NM_005470 spectrin SH3 domain binding protein 1 
ABP1 NM_001091   
ACADM NM_001127328 acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain 
ACAN NM_001135 formerly AGC1 
ACCS NM_032592 1-aminocyclopropane-1-carboxylate synthase ; formerly PHACS 
ACP1 NM_004300 Acid phosphatase 1, soluble 
ACSL6 NM_001009185 fatty-acid-coenzyme A ligase, long-chain 6; FACL6 
ADAM12 NM_003474 ADAM metallopeptidase domain 12  
ADRBK2 NM_005160   
AFF1 
NM_005935  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 2 (AF4) 
AFF3 NM_002285 lymphoid nuclear protein related to AF4; formerly LAF4 
AFF4 NM_014423 ALL1 fused gene from 5q31 (formerly AF5q31) 
AGT NM_000029   
AIM1 NM_001624   
Alk NM_004304   
ALPK2 NM_052947 HAK 
ALPK3 NM_020778 MIDORI 
ALS2CL NM_147129 ALS2 C-terminal like  
AMFR NM_001144 autocrine motility factor receptor  
ARAF NM_001654   
ARFGAP1 NM_175609 RPA human homolog 
ARFGEF2 NM_006420   
ARHGAP25 NM_001007231   
ARHGAP26 
NM_015071 Rho GTPase activating protein 26;Formerly known as GRAF or GTPase 
regulator associated with focal adhesion kinase pp125(FAK) 
ARHGEF12 NM_015313 RHO guanine nucleotide exchange factor (GEF) 12 (LARG) 
ARHGEF4 NM_032995 Rho guanine nucleotide exchange factor (GEF) 4  
ARL4C NM_025144 LAK 
ARNTL NM_001030273 Aryl hydrocarbon receptor nuclear translocator-like; formerly BMAL1 
ASL NM_001024943 argininosuccinate lyase  
ATF1 NM_005171 activating transcription factor 1 
ATIC 
NM_004044 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP 
cyclohydrolase 
ATN1 NM_001940   
ATP8B1 NM_005603 ATPase, Class I, type 8B, member 1 
ATR NM_001184   
AURKA NM_198433   
AURKB NM_004217   
AURKC NM_001015878   
AXL NM_001699   
BAI1 NM_001702 Brain-specific angiogenesis inhibitor 1 
! AB!
BAT2 NM_080686   
BAX NM_138764 BCL2-associated X protein 
BCL10 NM_003921 B-cell CLL/lymphoma 10 
BCL11A NM_022893 B-cell CLL/lymphoma 11A 
BCL11B NM_138576 B-cell CLL/lymphoma 11B  (CTIP2) 
BCL2 NM_000633 B-cell CLL/lymphoma 2 
BCL3 NM_005178 B-cell CLL/lymphoma 3 
BCL6 NM_001706 B-cell CLL/lymphoma 6 
BCL7A NM_020993 B-cell CLL/lymphoma 7A 
BCL9 NM_004326 B-cell CLL/lymphoma 9 
BCR NM_004327 breakpoint cluster region 
BGN NM_001711 biglycan 
BIRC3 NM_001165 baculoviral IAP repeat-containing 3 
BLK NM_001715   
BLM NM_000057 Bloom Syndrome 
BMP2K NM_198892 formerly BIKE 
BMPR1A NM_004329 bone morphogenetic protein receptor, type IA 
BMPR1B NM_001203   
BMPR2 NM_001204   
BRAF NM_004333 v-raf murine sarcoma viral oncogene homolog B1 
BRCA1 NM_007295 breast cancer 1, early onset  
BRCA2 NM_000059 familial breast/ovarian cancer gene 2 
BRD2 NM_005104 NM_005104 
BRD3 NM_007371 NM_007371 
BRDT NM_001726   
BRIP1 NM_032043 BRCA1 interacting protein C-terminal helicase 1 
BRSK1 NM_032430   
BTK NM_000061   
C14orf100 NM_016475   
C15orf55 NM_175741 nuclear protien in testis; formerly NUT 
C1orf64 NM_178840 chromosome 1 open reading frame 64; aka MGC24047 
C5orf42 NM_023073 FLJ13231 
C9ORF96 NM_153710 MGC43306 
CACNA1F NM_005183   
CAMK1 NM_003656   
CAMK1D NM_020397   
CAMK1G NM_020439   
CAMK2A NM_015981   
CAMK2B NM_001220   
CAMK2G NM_001222   
CAMK4 NM_001744   
CAMKK2 NM_006549   
CAMKV NM_024046 MGC8407 
CARD11 NM_032415 caspase recruitment domain family, member 11 
CASK NM_003688   
CATSPERB NM_024764 C14orf161 
CCDC6 NM_005436 DNA segment on chromosome 10 (unique) 170, H4 gene (PTC1); D10S170 
CCNB1IP1 
NM_182851 cyclin B1 interacting protein 1;formerly HEI10 or enhancer of invasion 10 - 
fused to HMGA2 
CCND1 NM_053056 cyclin D1 
CCND2 NM_001759 cyclin D2 
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CCND3 NM_001760 cyclin D3 
CCNL1 NM_020307 PRO1073 protein (ALPHA)  
CD46 NM_002389 CD46 molecule, complement regulatory protein; formerly MCP 
CD93 NM_012072 C1QR1 
CD97 NM_078481   
CDC42BPA NM_014826   
CDC42BPB NM_006035   
CDC42BPG NM_017525.1 DMPK2 
CDC7 NM_003503 cdc7l1 
CDC73 NM_024529 hyperparathyroidism 2 formerly HRPT2 
CDH1 NM_004360 cadherin 1, type 1, E-cadherin (epithelial) (ECAD) 
CDH10 NM_006727 cadherin 10, type 2 (T2-cadherin) 
CDH11 NM_001797 cadherin 11, type 2, OB-cadherin (osteoblast) 
CDH20 NM_031891 cadherin 20, type 2 
CDK2 NM_001798   
CDK3 NM_001258   
CDK4 NM_000075   
CDK6 NM_001259   
CDK8 NM_001260   
CDKL2 NM_003948   
CDKL3 NM_016508   
CDKL5 NM_003159   
CDKN2A NM_000077 cyclin-dependent kinase inhibitor 2A (p16(INK4a)) gene 
CEBPA NM_004364 CCAAT/enhancer binding protein (C/EBP), alpha 
CENTB1 NM_014716 centaurin, beta 1 
CENTG1 NM_001122772 centaurin, gamma 1 
CEP110 NM_007018 centrosomal protein 110kda aka cep1 
CFP NM_002621 complement factor properdin, PFC 
CHD5 NM_001795 chromodomain helicase DNA binding protein 5 
CHEK2 NM_001005735 CHK2 checkpoint homolog (S. pombe) 
CHUK NM_001278   
CIC NM_015125 capicua homolog  
CIITA NM_000246 MHC class II transactivator; formerly MHC2TA 
CIT NM_007174   
CLCN3 NM_001829   
CLP1 
NM_006831 CLP1, cleavage and polyadenylation factor I subunit, homolog (S. 
cerevisiae); formerly HEAB or ATP_GTP binding protein 
CNBP NM_001127192 zinc finger protein 9 (a cellular retroviral nucleic acid binding protein) 
CNNM4 NM_020184 cyclin M4  
CNTN3 NM_020872   
CNTN6 NM_014461 contactin 6 
COL11A1 NM_080629 collagen, type XI, alpha 1  
COL19A1 NM_001858 collagen, type XIX, alpha 1 
COL1A1 NM_000088 collagen, type I, alpha 1 
COL7A1 NM_000094 collagen, type VII, alpha 1 
COX6C NM_004374 cytochrome c oxidase subunit VIc 
CREB1 NM_134442 cAMP responsive element binding protein 1 
CREB3L2 NM_194071 cAMP responsive element binding protein 3-like 2 
CREBBP NM_004380 CREB binding protein (CBP) 
CRKRS NM_016507 CRK7 
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CRTC1 
NM_001098482 CREB regulated transcription coactivator 1; formerly MECT1 
mucoepidermoid translocated 1 
CRY1 NM_004075 Cryptochrome 1 (photolyase-like) 
CRY2 NM_021117 Cryptochrome 2 (photolyase-like) 
CSF1R NM_005211   
CSH2 NM_022644 Chorionic somatomammotropin hormone 2 
CSK NM_004383   
CSNK1A1 NM_001892   
CSNK1D NM_001893   
CSNK1E NM_001894   
CSPP1 NM_024790   
CUBN NM_001081 cubilin (intrinsic factor-cobalamin receptor) 
CUX1 NM_001913 CUTL1 
CXCR7 NM_020311 chemokine orphan receptor 1 
CYB5R4 NM_016230 cytochrome b5 reductase 4; formerly ncb5or 
CYP1A1 NM_000499 cytochrome P450, family 1, subfamily A, polypeptide 1 
DAPK1 NM_004938   
DAPK2 NM_014326   
DAPK3 NM_001348   
DBN1 NM_080881 drebrin 1  
DCLK1 AF052152 formerly dcamkl1 
DCLK3 NM_033403 formerly dcamkl3 
DDB1 NM_001923 Damage-specific DNA binding protein 1, 127kDa 
DDB2 NM_000107 damage-specific DNA binding protein 2 
DDIT3 NM_004083 DNA-damage-inducible transcript 3 
DDR1 NM_013993   
DDR2 NM_006182   
DDX10 NM_004398 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10  
DEK NM_003472 DEK oncogene (DNA binding) 
DHH NM_021044 Desert hedgehog homolog (Drosophila) 
DIP2C NM_014974 DIP2 disco-interacting protein 2 homolog C; aka KIAA0934 
DIRAS1 NM_145173 DIRAS family, GTP-binding RAS-like 1 
DIRAS2 NM_017594 DIRAS family, GTP-binding RAS-like 2 
DMPK NM_004409   
DNAH9 NM_001372 dynein, axonemal, heavy polypeptide 9 
DNAJC24 NM_181706 DPH4, JJJ3 homolog (S. cerevisiae); formerly ZCSL3 zinc finger, CSL-type 
containing 3 
DNASE1L3 NM_004944 deoxyribonuclease I-like 3 
DPAGT1 NM_001382   
DPYD NM_000110   
DUSP7 NM_001947   
DYRK1B NM_006484   
DYRK2 NM_006482   
DYRK3 NM_003582   
DYRK4 NM_003845   
E2F1 NM_005225 E2F transcription factor 1 
EEF2K NM_013302   
EGFL6 NM_015507 EGF-like-domain, multiple 6 
EHMT1 NM_024757 euchromatic histone-lysine N-methyltransferase 1 
EIF2AK2 NM_002759 PRKR 
EIF2AK4 NM_001013703   
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ELN NM_000501 elastin 
EMR1 NM_001974 Egf-like module containing, mucin-like, hormone receptor-like 1 
EPHA1 NM_005232   
EPHA10 NM_001004338   
EPHA2 NM_004431   
EPHA4 NM_004438   
EPHA5 NM_004439   
EPHA6 XM_114973   
EPHA7 NM_004440   
EPHA8 NM_020526   
EPHB1 NM_004441   
EPHB2 NM_017449   
EPHB3 NM_004443   
EPHB4 NM_004444   
EPS15 NM_001981 epidermal growth factor receptor pathway substrate 15 (AF1p) 
ERAS NM_181532 ES cell expressed Ras 
ERBB2 NM_004448   
ERBB3 NM_001982   
ERBB4 NM_005235   
ERC1 NM_178037 ELKS protein 
ERCC2 
NM_000400 excision repair cross-complementing rodent repair deficiency, 
complementation group 2 (xeroderma pigmentosum D) 
ERCC3 
NM_000122 excision repair cross-complementing rodent repair deficiency, 
complementation group 3 (xeroderma pigmentosum group B 
complementing) 
ERCC4 
NM_005236 excision repair cross-complementing rodent repair deficiency, 
complementation group 4 
ERCC5 
NM_000123 excision repair cross-complementing rodent repair deficiency, 
complementation group 5 (xeroderma pigmentosum, complementation group 
G (Cockayne syndrome)) 
ERCC8 
NM_000082 Excision repair cross-complementing rodent repair deficiency, 
complementation group 8; formerly ERCC8 
ERG  NM_004449 v-ets erythroblastosis virus E26 oncogene like (avian) 
ERGIC3 NM_198398 ERGIC and golgi 3; formerly ERGIC and golgi 3  
ERICH1 NM_207332 glutamate-rich 1; formerly LOC157697 
ERN1 NM_001433   
ERN2 NM_033266   
ETV1 NM_004956 ets variant gene 1 
ETV4 NM_001079675 ets variant gene 4 (E1A enhancer binding protein, E1AF) 
ETV5 NM_004454 ets variant gene 5 
ETV6 NM_001987 ets variant gene 6 (TEL oncogene) 
EVI1 NM_001105078 ecotropic viral integration site 1 
EXOC3L 
NM_178516 exocyst complex component 3-like ; formerly hypothetical protein 
LOC283849 
EXOC4 NM_021807 exocyst complex component 4; formerly sec8l1 
FAM123B NM_152424 family with sequence similarity 123B formerly WTX 
FAM161A NM_032180 FLJ13305 
FAM171B NM_177454 KIAA1946 
FANCA NM_000135 Fanconi anemia, complementation group A 
FANCB NM_001018113 Fanconi anemia, complementation group B 
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FANCC NM_000136 Fanconi anemia, complementation group C 
FANCD2 NM_033084 Fanconi anemia, complementation group D2 
FANCE NM_021922 Fanconi anemia, complementation group E 
FANCF NM_022725 Fanconi anemia, complementation group F 
FANCG NM_004629 Fanconi anemia, complementation group G 
FANCI NM_001113378 Fanconi anemia, complementation group I 
FANCL NM_001114636 Fanconi anemia, complementation group L 
FANCM NM_020937 Fanconi anemia, complementation group M 
FAS NM_000043 tumor necrosis factor receptor superfamily, member 6 (FAS) (TNFRSF6) 
FASTK NM_006712 NM_025096 
FCRL4 
NM_031282 Fc receptor-like 4; formerly IRTA1 immunoglobulin superfamily receptor 
translocation associated 1 
FCRL5 NM_031281 Fc receptor-like 5 
FEN1 NM_004111   
FER NM_005246   
FGFR1 NM_000604   
FGFR1OP NM_007045 FGFR1 oncogene partner (FOP) 
FGFR2 NM_022970   
FGFR3 NM_000142   
FGFR4 NM_022963   
FGR NM_005248   
FH NM_000143 fumarate hydratase 
FLCN NM_144997 folliculin, Birt-Hogg-Dube syndrome; formerly BHD 
FLJ23356 NM_032237   
FLNA NM_001456   
FLNB NM_001457 filamin B, beta  
FLT1 NM_002019   
FLT3 NM_004119   
FLT4 NM_002020   
FOXO1 NM_002015 forkhead box O1A (FKHR) 
FOXO3 NM_001455 forkhead box O3A 
FOXO4 
NM_005938 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 7 (AFX1) 
FREM1 NM_144966   
FRK NM_002031   
FSCB NM_175741 chromosome 14 open reading frame 155 
FUS NM_004960 fusion, derived from t(12;16) malignant liposarcoma 
FYN NM_002037   
GAB1 AK074381 GRB2-associated binding protein 1 
GAK NM_005255   




GEM NM_005261 GTP binding protein overexpressed in skeletal muscle 
GEN1 NM_182625 hypothetical protein FLJ40869  
GGA1 NM_013365 golgi associated, gamma adaptin ear containing, ARF binding protein 1 
GJD4 NM_153368 CX40.1 
GLI1 NM_005269 glioma-associated oncogene homolog 1  
GLI2 NM_005270 GLI-Kruppel family member GLI2 
GPNMB NM_001005340 glycoprotein (transmembrane) nmb 
GPR64 NM_005756 G protein-coupled receptor 64; formerly HE6 
! YD!
GRIN2D NM_000836 glutamate receptor, ionotropic, N-methyl D-aspartate 2D 
GRK1 NM_002929 RHOK 
GRK4 NM_005307   
GRK5 NM_005308 GPRK5 
GRK6 NM_002082   
GRK7 NM_139209   
GSN NM_000177   gelsolin 
GUCY2C NM_004963   
GUCY2D NM_000180   
GUCY2F NM_001522   
HCK NM_002110   
HDAC4 CCDS2529.1 histone deacetylase 4 
HDLBP CCDS2547.1 high density lipoprotein binding protein  
HIPK1 NM_152696   
HIPK2 NM_022740   
HIPK3 NM_005734   
HNF1A NM_000545 HNF1 Homeobox A;transcription factor 1, hepatic; formerly tcf1 
HOXA3 NM_153631 homeobox A3  
HRAS NM_176795 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
HSP90AB1 BG393867 heat shock 90kDa protein 1, beta 
HSPB8 NM_014365 H11 
ICAM5 NM_003259 intercellular adhesion molecule 5, telencephalin  
ICK NM_016513   
IGF1R NM_000875   
IHH NM_002181 Indian hedgehog homolog (Drosophila) 
IKBKB NM_001556   
IKZF1 AF432219 zinc finger protein, subfamily 1A, 1 (Ikaros) 
IL2 NM_000586 interleukin 2 
IL21R NM_181078 interleukin 21 receptor 
INHBE NM_031479 inhibin, beta E 
INPP4A NM_001566 Inositol polyphosphate-4-phosphatase, type I, 107kDa 
INPP4B NM_003866 Inositol polyphosphate-4-phosphatase, type II, 105kDa 
INPP5B NM_005540 Inositol polyphosphate-5-phosphatase, 75kDa 
INPP5E NM_019892 Inositol polyphosphate-5-phosphatase, 72 kDa 
INSR NM_000208   
INSRR NM_014215   
IRAK1 NM_001569   
IRAK2 NM_001570   
IRAK3 NM_007199   
IRF4 NM_002460 interferon regulatory factor 4 
ITGA9 NM_002207 integrin, alpha 9  
ITK NM_005546   
JAK1 NM_002227   
JAK2 NM_004972   
JAK3 NM_000215   
JARID1B NM_006618   
JAZF1 NM_175061 juxtaposed with another zinc finger gene 1 
JTV1 NM_014413 HRI 
KALRN NM_007064   
KDR NM_002253   
! Y"!
KDSR 
NM_002035 3-ketodihydrosphingosine reductase; follicular lymphoma variant 
translocation 1 aka FVT1 
KEAP1 NM_203500 kelch-like ECH-associated protein 1 
KIAA0427 NM_014772 KIAA0427 
KIAA0467 NM_015284   
KIAA0664 NM_015229   
KIAA0774 NM_001033602   
KIAA0999 NM_025164 KIAA0999 protein  
KIAA1632 NM_020964 KIAA1632 
KIF14 NM_014875   
KIT NM_000222   
KLF6 NM_001300 core promoter element binding protein (KLF6); formerly COPEB 
KPNA5 NM_002269 karyopherin alpha 5 
KRT73 NM_175068 keratin 6 irs3 formerly k6irs3 
KSR1 NM_014238   
KSR2 NM_173598   
KTN1 NM_182926 kinectin 1 
LASP1 NM_006148 LIM and SH3 protein 1 
LATS1 NM_004690   
LATS2 NM_014572   
LCK NM_005356   
Lig1 NM_000234   
Lig3 NM_013975   
LIMK1 NM_016735   
LMTK2 NM_014916 Lemur tyrosine kinase 2 
LMTK3 NM_001080434 Lemur tyrosine kinase 3 
LRBA NM_006726 LPS-responsive vesicle trafficking, beach and anchor containing 
LRRC7 NM_020794   
LRRFIP1 NM_004735 leucine rich repeat (in FLII) interacting protein 1 
LRRK1 NM_024652 FLJ23119 
LRRK2 XM_058513   
LTK NM_002344   
LYN NM_002350   
MACF1 NM_033044 microtubule-actin crosslinking factor 1 
MAGEE1 NM_020932 melanoma antigen family E, 1 
MAK NM_005906   
MAMDC4 NM_206920 MAM domain containing 4  
MAML2 NM_032427 mastermind-like 2 (Drosophila) 
MAP2K4 NM_003010   
MAP2K7 NM_005043   
MAP3K1 XM_042066   
MAP3K10 NM_002446   
MAP3K11 NM_002419   
MAP3K12 NM_006301   
MAP3K13 NM_004721   
MAP3K14 NM_003954   
MAP3K15 NM_001001671 SK681 
MAP3K2 NM_006609   
MAP3K3 NM_002401   
MAP3K4 NM_005922   
MAP3K6 NM_004672 mitogen-activated protein kinase kinase kinase 6 
! YT!
MAP3K9 NM_033141   
MAP4K1 NM_007181   
MAP4K3 NM_003618   
MAP4K4 NM_145686   
MAP4K5 NM_006575   
MAPK7 NM_002749   
MAPK8 NM_002750   
MAPK9 NM_002752   
MAPKAPK3 NM_004635   
MAPKBP1 NM_014994   
MARK1 NM_018650   
MARK2 NM_017490   
MARK3 NM_002376   
MARK4 NM_031417   
MAST1 NM_014975   
MAST2 NM_015112   
MAST3 XM_038150   
MAST4 XM_291141   
MASTL NM_032844   
MATK NM_139355   
MBD4 NM_003925   
MC1R NM_002386 Melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) 
MDM2 NM_002392 Mdm2 p53 binding protein homolog (mouse) 
MDS1 NM_004991 myelodysplasia syndrome 1 
MELK NM_014791   
MEN1 NM_130803 multiple endocrine neoplasia type 1 gene 
MERTK NM_006343   
MET NM_000245   
MGC16169 NM_033115 TBCK 
MGC42105 NM_153361   
MGMT NM_002412   
MINK1 NM_015716   
MLH1 NM_000249 E.coli MutL homolog gene 
MLKL NM_152649   
MLL 
NM_005933 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila) 
MN1 NM_002430 meningioma (disrupted in balanced translocation) 1 
MNX1 NM_005515 homeo box HB9 
MOS NM_005372   
MRAS NM_012219 Muscle RAS oncogene homolog 
MRE11A NM_005590 MRE11 meiotic recombination 11 homolog A 
MSH2 NM_000251 mutS homolog 2 (E. coli) 
MSH4 NM_002440 MutS homolog 4 (E. coli) 
MSH6 NM_000179 mutS homolog 6 (E. coli) 
MST1R NM_002447   
MST4 NM_016542   
MTMR14 NM_001077525 Myotubularin related protein 14 
MTMR3 NM_021090 myotubularin related protein 3  
MUSK NM_005592   
MYC NM_002467 v-myc myelocytomatosis viral oncogene homolog (avian) 
MYH1 NM_005963 myosin, heavy polypeptide 1, skeletal muscle, adult  
! YU!
MYLK NM_053025   
MYLK4 XM_373109 SgK085 
MYO19 NM_001033579 MYOHD1 
MYO1G NM_033054   
MYO3A NM_017433   
MYO3B NM_138995   
MYOD1 NM_002478 myogenic differentiation 1 
MYST3 
NM_001099412 MYST histone acetyltransferase (monocytic leukemia) 3;formerly Runxbp2 
runt-related transcription factor binding protein 2 (MOZ/ZNF220) 
MYST4 NM_012330 MYST histone acetyltransferase (monocytic leukemia) 4 (MORF) 
NBN NM_002485 Nijmegen breakage syndrome 1 (nibrin) 
NCOA6 NM_014071 nuclear receptor coactivator 6 
NEIL1 NM_024608 Nei endonuclease VIII-like 1 (E. coli) 
NEIL2 NM_145043 Nei like 2 (E. coli) 
NEIL3 NM_018248 Nei endonuclease VIII-like 3 (E. coli) 
NEK1 NM_012224   
NEK10 NM_152534   
NEK11 NM_024800   
NEK4 NM_003157   
NEK6 NM_014397   
NEK7 NM_133494   
NEK8 NM_178170   
NEK9 NM_033116   
NF2 NM_181832 neurofibromatosis type 2 gene 
NKIRAS1 NM_020345 NFKB inhibitor interacting Ras-like 1 
NKIRAS2 NM_001001349 NFKB inhibitor interacting Ras-like 2 
NLE1 NM_001014445 notchless homolog 1, aka FLJ10458 
NLK NM_016231   
NLRP8 NM_176811 NACHT, leucine rich repeat and PYD containing 8; formerly NALP8 
NOTCH1 NM_017617 Notch homolog 1, translocation-associated (Drosophila) (TAN1) 
NPAT NM_000051 ataxia telangiectasia mutated, formerly ATM 
NPM1 NM_002520 nucleophosmin (nucleolar phosphoprotein B23, numatrin) 
NPR1 NM_000906   
NR4A3 NM_173198 nuclear receptor subfamily 4, group A, member 3 (NOR1) 
NRAS NM_002524 neuroblastoma RAS viral (v-ras) oncogene homolog 
NRBP1 NM_013392   
NRBP2 NM_178564   
NRCAM NM_001037132 neuronal cell adhesion molecule  
NTRK1 NM_002529   
NTRK2 NM_006180   
NTRK3 NM_002530   
NUAK2 NM_030952 SNARK 
NUMA1 NM_006185 nuclear mitotic apparatus protein 1 
NUP133 NM_018230 nucleoporin 133kDa  
NUP214 NM_005085 nucleoporin 214kDa  
OCA2 NM_000275 Oculocutaneous albinism II 
OCRL NM_000276 Oculocerebrorenal syndrome of Lowe 
OGG1 NM_016819 8-oxoguanine DNA glycosylase 
OSR1 NM_005109   
OTOF NM_194248 otoferlin 
PAK1 NM_002576   
! YV!
PAK3 NM_002578   
PAK6 NM_020168   
PAK7 NM_020341   
PALB2 NM_024675 partner and localizer of BRCA2 
PARG NM_003631   
PARP1 NM_001618   
PARP2 NM_005484   
PASK NM_015148   
PATZ1 NM_014323 POZ (BTB) and AT hook containing zinc finger 1; formerly ZNF278 
PAX3 NM_181458 paired box gene 3  
PAX5 NM_016734 paired box gene 5 (B-cell lineage specific activator protein) 
PAX7 NM_002584 paired box gene 7 
PAX8 NM_003466 paired box gene 8 
PBX1 NM_002585 pre-B-cell leukemia transcription factor 1 
PCDHB15 NM_018935 protocadherin beta 15 
PCM1 NM_006197 pericentriolar material 1  (PTC4) 
PCNA NM_002592 Proliferating cell nuclear antigen 
PCTK2 NM_002595   
PDCD11 NM_014976   
PDGFB 
NM_002608 platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) 
oncogene homolog) 
PDGFRA NM_006206   
PDGFRB NM_002609   
PDIK1L NM_152835   
PDK2 NM_002611   
PDK3 NM_005391   
PDPK1 NM_002613   
PDXK NM_003681 PNK 
PER1 NM_002616 period homolog 1 (Drosophila) 
PER2 NM_022817 Period homolog 2 (Drosophila) 
PER3 NM_016831 Period homolog 3 (Drosophila) 
PFTK1 NM_012395   
PHKG1 NM_006213   
PICALM NM_007166 phosphatidylinositol binding clathrin assembly protein (CALM) 
PIK3C2A  NM_002645  CPK, PI3-K-C2A, PI3K-C2alpha 
PIK3C2B  NM_002646  C2-PI3K, PI3K-C2beta 
PIK3C2G  NM_004570  PI3K-C2-gamma 
PIK3C3  NM_002647  Vps34 
PIK3CA  NM_006218  p110-alpha 
PIK3CB  NM_006219  PIK3C1, p110-beta 
PIK3CD  NM_005026  p110-delta 
PIK3CG  NM_002649  PI3CG, PI3K-gamma 
PIK3R4 NM_014602   
PIM1 NM_002648   
PIM2 NM_006875   
PINK1 NM_032409   
PKDREJ 
NM_006071 polycystic kidney disease (polycystin) and REJ (sperm receptor for egg jelly 
homolog, sea urchin)-like 
PKN1 NM_002741 PRKCL1 
PKN2 NM_006256 PRKCL2 
PKN3 NM_013355   
! YB!
PLD2 NM_002663   
PLEKHA8 NM_032639 pleckstrin homology domain containing, family A 
PLK1 NM_005030   
PLK2 NM_006622 SNK 
PLK3 NM_004073   
PML NM_033238 promyelocytic leukemia 
PMS1 NM_000534 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 
PMS2 NM_000535 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) 
PNCK NM_198452 CaMK1b 
POLB NM_002690   
PPAP2B NM_003713 Phosphatidic acid phosphatase type 2B 
PPM1E NM_014906 protein phosphatase 1E  
PRDM16 NM_022114 PR domain containing 16 
PRKAA2 NM_006252   
PRKACB NM_002731   
PRKAR1A 
NM_212472 protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific 
extinguisher 1) 
PRKCA NM_002737   
PRKCB NM_002738   
PRKCG NM_002739   
PRKCH NM_006255   
PRKCI NM_002740   
PRKCQ NM_006257   
PRKCZ NM_002744   
PRKD2 NM_016457   
PRKD3 NM_005813   
PRKDC NM_006904   
PRKG1 NM_006258   
PRKG2 NM_006259   
PRMT1 NM_198319   
PRMT6 NM_018137   
PRPF4B NM_003913 PRP4 pre-mRNA processing factor 4 homolog B 
PRPS1 NM_002764 phosphoribosyl pyrophosphate synthetase 1 
PRRX1 NM_006902 paired mesoderm homeo box 1 
PRUNE2 NM_015225 KIAA0367 
PSIP1 NM_033222 PC4 and SFRS1 interacting protein 2 (LEDGF) 
PSKH2 NM_033126   
PTCH1 NM_001083602 Homolog of Drosophila Patched gene 
PTEN NM_000314 phosphatase and tensin homolog gene 
PTK2 NM_005607   
PTK2B NM_004103   
PTK6 NM_005975   
PTK7 NM_002821   
PTPN13 NM_080685   
PTPN14 NM_005401 protein tyrosine phosphatase, non-receptor type 14 
PTPN18 NM_014369   
PTPN20B NM_015605.2 DKFZP566K0524 
PTPN3 NM_002829.2   
PTPRF NM_002840   
PTPRG NM_002841   
PTPRT NM_133170   
! YA!
RABEP1 NM_004703 rabaptin, RAB GTPase binding effector protein 1 (RABPT5) 
RAD23B NM_002874 RAD23 homolog B (S. cerevisiae) 
Rad50 NM_005732   
Rad51 NM_002875   
RAD51L1 NM_133509 RAD51-like 1 (S. cerevisiae) (RAD51B) 
RAD52 NM_134424   
RAF1 NM_002880   
RAGE NM_014226   
RALA NM_005402 V-ral simian leukemia viral oncogene homolog A (ras related) 
RALB NM_002881 V-ral simian leukemia viral oncogene homolog B (ras related; GTP binding 
protein) 
RALBP1 NM_006788 RalA binding protein 1 
RAP1A NM_001010935 RAP1A, member of RAS oncogene family 
RAP1B NM_015646 RAP1B, member of RAS oncogene family 
RAP1GAP NM_002885 RAP1 GTPase activating protein  
RAP2A NM_021033 RAP2A, member of RAS oncogene family 
RAP2B NM_002886 RAP2B, member of RAS oncogene family 
RAP2C NM_021183 RAP2C, member of RAS oncogene family 
RAPH1 NM_213589 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 
RASAL2 NM_170692 RAS protein activator like 2 
RASD1 NM_016084 RAS, dexamethasone-induced 1 
RASD2 NM_014310 RASD family, member 2 
RASGRF2 NM_006909 Ras protein-specific guanine nucleotide-releasing factor 2  
RASL10A NM_001007279 RAS-like, family 10, member A 
RASL10B NM_033315 RAS-like, family 10, member B 
RASL11A NM_206827 RAS-like, family 11, member A 
RASL11B NM_023940 RAS-like, family 11, member B 
RASL12 NM_016563 RAS-like, family 12 
RASSF1 NM_170714 Ras association (RalGDS/AF-6) domain family member 1 
RASSF10 NM_001080521 Ras association (RalGDS/AF-6) domain family (N-terminal) member 10 
RASSF2 NM_014737 Ras association (RalGDS/AF-6) domain family member 2 
RASSF3 NM_178169 Ras association (RalGDS/AF-6) domain family member 3 
RASSF4 NM_032023 Ras association (RalGDS/AF-6) domain family member 4 
RASSF5 NM_182663 Ras association (RalGDS/AF-6) domain family member 5 
RASSF6 NM_201431 Ras association (RalGDS/AF-6) domain family member 6 
RASSF7 NM_003475 Ras association (RalGDS/AF-6) domain family (N-terminal) member 7 
RASSF8 NM_007211 Ras association (RalGDS/AF-6) domain family (N-terminal) member 8 
RASSF9 NM_005447 Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 
RB1 NM_000321 retinoblastoma gene 
RBL1 NM_002895 Retinoblastoma-like p107 
RBL2 NM_005611 Retinoblastoma-like 2 (p130) 
RBM15 NM_022768 RNA binding motif protein 15 
REC8 NM_001048205   
RECQL4 NM_004260 RecQ protein-like 4 
REM1 NM_014012 RAS (RAD and GEM)-like GTP-binding 1 
REM2 NM_173527 RAS (RAD and GEM)-like GTP binding 2 
RERG NM_032918 RAS-like, estrogen-regulated, growth inhibitor 
RFX2 NM_000635 regulatory factor X, 2  
RGL1 NM_015149 ral guanine nucleotide dissociation stimulator-like 1 
RHEB AF148645 Ras homolog enriched in brain 
RHEBL1 NM_144593 Ras homolog enriched in brain like 1 
! YY!
RIMS2 NM_014677   
RIOK2 NM_018343   
RIPK1 NM_003804   
RIPK3 NM_006871   
RIPK5 NM_015375   
RIT1 NM_006912 Ras-like without CAAX 1 
RIT2 NM_002930 Ras-like without CAAX 2 
RNASEL NM_021133   
RNF219 NM_024546 C13orf7 
ROCK1 NM_005406   
ROCK2 NM_004850   
ROR1 NM_005012   
ROR2 NM_004560   
ROS1 NM_002944   
RP1L1 NM_178857   
RPGRIP1 NM_020366   
RPL22   ribosomal protein L22 (EAP) 
RPS6KA2 NM_021135   
RPS6KA3 NM_004586   
RPS6KA4 NM_003942   
RPS6KA6 NM_014496   
RPS6KB2 NM_003952   
RPS6KC1 NM_012424   
RRAD NM_004165 Ras-related associated with diabetes 
RRP9 
NM_004704 ribosomal RNA processing 9, small subunit (SSU) processome component, 
homolog (yeast); formerly RNU3IP2 RNA, U3 small nucleolar interacting 
protein 2 
RUNX1 NM_001001890  runt-related transcription factor 1  (AML1) 
RYK NM_001005861 NM_002958 
SAR1A NM_020150 SAR1 gene homolog A (S. cerevisiae) 
SBDS NM_016038 Shwachman-Bodian-Diamond syndrome protein 
SBK1 NM_001024401   
SBNO1 NM_018183 sno, strawberry notch homolog 1 
SCNN1B NM_000336 sodium channel, nonvoltage-gated 1, beta  
SCYL1 NM_020680   
SCYL2 NM_017988   
SDHB NM_003000 succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 
SDHC 




succinate dehydrogenase complex, subunit D, integral membrane protein 
SEMA5B NM_001031702 semaphorin 5B  
SEPHS2 NM_012248   
SEPT6 NM_145799 septin 6 
SERPINB1 NM_030666 serpin peptidase inhibitor, clade B (ovalbumin), member 1 
SGK1 NM_005627   
SGK2 NM_016276   
SgK269 XM_370878   
SGK3 NM_013257 SGKL 
SH3GL1 NM_003025 SH3-domain GRB2-like 1 (EEN) 
SHH NM_000193 Sonic hedgehog homolog (Drosophila) 
! Y]!
SIN3B NM_015260 SIN3 homolog B, transcription regulator (yeast) 
SIX4 NM_017420 sine oculis homeobox homolog 4 
SKIP NM_130766 Skeletal muscle and kidney enriched inositol phosphatase 
SLC24A4 NM_153646 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 
SLC24A5 NM_205850 Solute carrier family 24, member 5 
SLC44A4 NM_025257 solute carrier family 44, member 4, formerly c6orf29 
SLC6A3 NM_001044 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 
SLC8A3 NM_182932   
SLC9A10 NM_183061   
SLC9A2 NM_003048 solute carrier family 9 (sodium/hydrogen exchanger), member 2 
SLK NM_014720   
SMARCB1 
NM_003073 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily b, member 1 
SMG1 NM_015092   
SMUG1 NM_014311   
SNF1LK NM_173354   
SNF1LK2 NM_015191   
SNRK NM_017719   
SOCS1 NM_003745 suppressor of cytokine signaling 1  
SORL1 NM_003105 sortilin-related receptor, L(DLR class) A repeats-containing  
SP110 NM_080424 SP110 nuclear body protein  
SPECC1 NM_001033553 sperm antigen HCMOGT-1 
SPEG NM_005876 APEG1 
SPTAN1 NM_003127 spectrin, alpha, non-erythrocytic 1 
SRPK2 NM_003138   
STARD8 NM_014725 START domain containing 8 
STIL NM_001048166 TAL1 (SCL) interrupting locus 
STK10 NM_005990   
STK11 NM_000455   
STK16 NM_003691   
STK17B NM_004226   
STK19 NM_032454   
STK3 NM_006281   
STK31 NM_031414   
STK32A NM_145001 YANK1 
STK32B NM_018401   
STK33 NM_030906   
STK35 NM_080836   
STK36 NM_015690   
STK38 NM_007271   
STK38L NM_015000   
STK39 NM_013233   
STYK1 NM_018423   
SUFU NM_016169 suppressor of fused homolog (Drosophila) 
SULF2 NM_018837 sulfatase 2 
SYK NM_003177   
SYNE2 NM_182914 spectrin repeat containing, nuclear envelope 2 
SYNJ1 NM_203446 Synaptojanin 1 
SYNJ2 NM_003898 Synaptojanin 2 
SYT14L NM_001014372 CHR415SYT 
TACC2 NM_206862   
! Y[!
TAF1 NM_138923   
TAF15 
NM_003487 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 68kDa 
TAF1L NM_153809   
TAOK1 NM_020791   
TAOK2 NM_004783 TAO1 
TAOK3 NM_016281   
TBK1 NM_013254   
TBPL1 NM_004865 TBP-like 1 
TDG NM_003211   
Tdp1 NM_018319   
TDRD6 NM_001010870   
TEC NM_003215   
TECTA NM_005422 tectorin alpha  
TEK NM_000459   
TERF2 NM_005652 Telomeric repeat binding factor 2 
TESK1 NM_006285   
TESK2 NM_007170   
TET1 AL713658 leukemia-associated protein with a CXXC domain 
TEX14 NM_031272   
TFE3 NM_006521 transcription factor binding to IGHM enhancer 3 
TFEB NM_007162 transcription factor EB 
TFG NM_006070 TRK-fused gene 
TG NM_003235   
TGFBR1 NM_004612   
THBS3 NM_007112 thrombospondin 3  
THOC5 NM_001002878 THO complex 5, formerly c22orf19 
TIE1 NM_005424   
TIMELESS NM_003920   
TLK1 NM_012290   
TLK2 NM_006852   
TLN1 NM_006289   
TMEM123 NM_052932   
TMPRSS2 NM_005656 transmembrane protease, serine 2 
TMPRSS6 NM_153609 transmembrane protease, serine 6 
TNFRSF17 NM_001192 tumor necrosis factor receptor superfamily, member 17 
TNIK NM_015028   
TNK1 NM_003985   
TNNI3k NM_015978   
TOP1 NM_003286 topoisomerase (DNA) I 
TP63 NM_003722 Tumor protein p63 
TP73 NM_005427 Tumor Protein 73 
TPM3 NM_152263 tropomyosin 3 
TPR NM_003292 translocated promoter region  
TPTE2 NM_199254 Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 
TRIB1 NM_025195   
TRIB3 NM_021158   
TRIM24 NM_003852 TIF1 
TRIM33 NM_015906   
TRIO NM_007118   
TRPM6 NM_017662   
! ]D!
TRPM7 NM_017672   
TRRAP NM_003496   
TSC1 NM_000368 tuberous sclerosis 1 gene 
TSC2 NM_000548 tuberous sclerosis 2 gene 
TSHR NM_000369 thyroid stimulating hormone receptor 
TSSK1B NM_032028 STK22D 
TTBK1 NM_032538   
TTBK2 NM_173500   
TTK NM_003318   
TTL NM_153712 tubulin tyrosine ligase 
TWF1 NM_002822 PTK9 
TWF2 NM_007284 PTK9L 
TYK2 NM_003331   
TYR NM_000372 Tyrosinase (oculocutaneous albinism IA) 
TYRO3 NM_006293   
UBQLNL NM_145053 MGC20470 
UBR5 NM_015902 EDD1 
ULK1 NM_003565   
ULK2 NM_014683   
ULK3 NM_015518   
UNG NM_003362   
USP1 NM_003368 Ubiquitin specific peptidase 1 
USP6 NM_004505 ubiquitin specific peptidase 6 (Tre-2 oncogene) 
VEPH1 NM_024621 ventricular zone expressed PH domain homolog 1 
VHL NM_000551 von Hippel-Lindau syndrome gene 
VIPR1 NM_004624 Vasoactive intestinal peptide receptor 1 
VRK1 NM_003384   
WDR91 NM_014149 HSPC049 
WEE1 NM_003390   
wnk1 NM_018979 PRKWNK1 
wnk2 NM_006648 PRKWNK2 
wnK3 NM_020922 PRKWNK3 
wnk4 NM_032387 PRKWNK4 
WRN NM_000553 Werner syndrome (RECQL2) 
WT1 NM_024426 Wilms tumour 1 gene 
XDH NM_000379 xanthine dehydrogenase  
XIRP1 NM_194293 formerly cmya1; xin actin-binding repeat containing 1 
XPA NM_000380 xeroderma pigmentosum, complementation group A 
XPC NM_004628 xeroderma pigmentosum, complementation group C 
XRCC1 NM_006297   
XRCC3 NM_001100119   
YSK4 NM_025052 FLJ23074 
ZAP70 NM_001079   
ZBTB16 
NM_006006 zinc finger and BTB domain containing 16; zinc finger protein 145 (PLZF); 
formerly znf145 
ZFP64 NM_018197 zinc finger protein 64 homolog  
ZFYVE26 NM_015346 zinc finger, FYVE domain containing 26  
ZMYM2 NM_006006 Zinc finger, MYM-type 2; formerly ZNF198 zinc finger protein 198 
ZMYM4 NM_005095 ZNF262 
ZNF318 NM_014345 zinc finger protein 318  
ZNF331 NM_018555 zinc finger protein 331 
! ]"!
ZNF384 NM_001039916 zinc finger protein 384 (CIZ/NMP4) 
ZNF521 NM_015461 zinc finger protein 521 
ZNF569 NM_152484 zinc finger protein 569  
ZNF646 NM_014699   
ZNF668 NM_024706 zinc finger protein 668, aka FLJ13479 
NCKIPSD 
NM_016453 SH3 protein interacting with Nck, 90 kDa (ALL1 fused gene from 3p21), 
formerly AF3p21 
GAS7 NM_201433 growth arrest-specific 7 
PPARG NM_138711 peroxisome proliferative activated receptor, gamma 
AKAP9 NM_147171 A kinase (PRKA) anchor protein (yotiao) 9 
CTNNB1 NM_001904 catenin (cadherin-associated protein), beta 1 
EP300 NM_001429 300 kd E1A-Binding protein gene 
FSTL3 NM_005860 follistatin-like 3 (secreted glycoprotein) 
HIST1H4I NM_003495 histone 1, H4i (H4FM) 
NIN NM_020921 ninein (GSK3B interacting protein) 
NCOA1 NM_147223 nuclear receptor coactivator 1 
NCOA2 NM_006540 nuclear receptor coactivator 2 (TIF2) 
NCOA4 AK130612 nuclear receptor coactivator 4 - PTC3 (ELE1) 
MUTYH NM_012222 mutY homolog (E. coli) 
NSD1 NM_022455 nuclear receptor binding SET domain protein 1 
Sumo1     
CHIC2 NM_012110 cysteine-rich hydrophobic domain 2 
ELF4 NM_001421 E74-like factor 4 (ets domain transcription factor) 
MSI2 NM_170721 musashi homolog 2 (Drosophila) 
MSN NM_002444 moesin 
POU2AF1 NM_006235 POU domain, class 2, associating factor 1 (OBF1) 
POU5F1 NM_002701 POU domain, class 5, transcription factor 1 
RANBP17 NM_022897 RAN binding protein 17 
RAP1GDS1 NM_001100426 RAP1, GTP-GDP dissociation stimulator 1 
TCEA1 NM_006756 transcription elongation factor A (SII), 1 
TCF12 NM_207037 transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) 
TCF3 
NM_003200 transcription factor 3 (E2A immunoglobulin enhancer binding factors 
E12/E47) 
KCNAB2 NM_172130   
AK5 NM_012093   
DPP4 NM_001935   
IHPK3 NM_054111   
SLC26A4 NM_000441   
RGS3 NM_021106   
ARMCX2 NM_177949   
CNNM1 NM_020348   
RAB3D NM_004283   
CACNA1A NM_001127221   
DOK5 NM_018431   
TOM1 NM_005488   
TET3 NM_144993   
SOX11 NM_003108   
SHOX2 NM_003030   
NFE2L3 NM_004289   
SLC38A2 NM_018976   
MEIS2 NM_002399   
! ]T!
PIK3IP1 NM_052880   
!
